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Abstract
More than 20 individual and fixed-dose combinations of antiretrovirals are approved for the
treatment of human immunodeficiency virus (HIV) infection. However, owing to the ongoing
limitations of drug resistance and adverse effects, new treatment options are still required. A
number of promising new agents in existing or new drug classes are in development or have
recently been approved by the US FDA. Since these agents will be used in combination with other
new and existing antiretrovirals, understanding the potential for drug interactions between these
compounds is critical to their appropriate use. This article summarizes the drug interaction
potential of new and investigational protease inhibitors (darunavir), non-nucleoside reverse
transcriptase inhibitors (etravirine and rilpivirine), chemokine receptor antagonists (maraviroc,
vicriviroc and INCB 9471), integrase inhibitors (raltegravir and elvitegravir) and maturation
inhibitors (bevirimat).
Advances in the treatment of human immunodeficiency virus (HIV) infection include the
discovery of new antiretroviral agents and an improved understanding of the optimal
combination of these agents for therapeutic benefit. Currently, the most potent antiretroviral
regimens are those that include a combination of medications targeting different stages of
the HIV life cycle. In 2007, two new classes of antiretrovirals were approved by the US
FDA, and a number of other novel antiretrovirals in new classes and existing classes are
being developed. All of these drugs are promising options for treatment-experienced
patients. However, each class has a unique drug-interaction profile, making the optimal
combination of these drugs challenging. Encouragingly, some of these new agents are not
substrates of either cytochrome P450 (CYP) enzymes or drug transport proteins. This
increases their potential to be used in combination with currently available antiretroviral
agents without concern for subtherapeutic or supratherapeutic exposures. This article
reviews the drug-drug interaction data, as well as drug-drug interaction potential, for
antiretrovirals that have recently become available or are currently undergoing later phase
clinical study. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors
(NNRTIs) are featured, as are new agents in the chemokine receptor antagonist class, the
integrase inhibitor class, and the maturation inhibitor class. A summary of interactions
between antiretrovirals can be found in tables I-III, and a summary of interactions between
these new antiretrovirals and concomitant medications is presented in table IV.
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Darunavir is a new protease inhibitor recently approved for the treatment of HIV-1-infected
patients. In the US, the approved dose of darunavir is 600 mg, administered in conjunction
with 100 mg of ritonavir, every 12 hours with food. Darunavir is recommended for use in
treatment-experienced (multiple protease inhibitor-resistant) adult patients (figure 1a).
1.1.1 Pharmacology—The molecular weight of darunavir is 593.73 g/mol.[1] Darunavir
maintains activity against multidrug-resistant strains of HIV-1. This may be due, in part, to
darunavir’s higher binding affinity to the HIV protease enzyme. The derived binding affinity
constant of darunavir is >0.0045 nmol/L, which is approximately 1000-fold greater than
those of indinavir, nelfinavir and saquinavir.[2] Darunavir maintains a binding affinity that
is more than 100-fold higher than those of amprenavir, atazanavir, lopinavir and tipranavir
in the presence of wild-type protease. Darunavir’s dissociative half-life from the protease
enzyme is also much higher (>240 hours) than those of other protease inhibitors, suggesting
that darunavir remains bound and active in vivo throughout the plasma elimination process.
[3]
The median concentration at which 50% of the maximum darunavir drug effect is achieved
(EC50) ranges from 1 to 8.5 nmol/L.[1] The 90% effective concentration ranges from 2.7 to
13 nmol/L.[2] Darunavir is approximately 95% bound to plasma α1-acid glycoprotein.[1] In
vitro observations of clinically relevant darunavir plasma concentrations at 4.7 to 52 base-
equivalent ng/mL found that the mean plasma protein binding of darunavir ranges from 92%
to 94%.[4] As expected, when darunavir concentrations increase within this in vitro system,
the fraction of unbound darunavir increases. A study of 118 HIV-positive, treatment-
experienced individuals calculated a median inhibitory quotient (IQ) of 36.3 (range 0.5–
1150), assuming 95% protein binding in the calculation of free drug concentration.[5]
In vitro, the major mechanism of darunavir absorption is through passive transcellular
diffusion. However, darunavir is both a substrate and an inhibitor of the enzyme P-
glycoprotein (with an apparent 50% inhibitory concentration [IC50] of 32.9 μmol/L, or 19
μg/mL). Since darunavir is coadministered with ritonavir (also a P-glycoprotein inhibitor), it
is possible that this combination could affect the intestinal absorption of other compounds
that are also substrates of P-glycoprotein.[6] However, no full-intensive pharmacokinetic
studies investigating any clinically relevant drug-drug interactions between darunavir/
ritonavir and other P-glycoprotein substrates have been conducted. Evaluation of the
function of the efflux transporter multidrug resistance protein (MRP) 1 in a group of seven
healthy volunteers who took 900 mg of darunavir and 100 mg of ritonavir once daily for 10
days resulted in decreased MRP1 expression without decreased messenger RNA expression
or efflux function in vivo. Compared with baseline, the geometric mean ratio (GMR) for
MRP1 expression declined by 0.58 (95% CI 0.51, 0.65; p < 0.001). The expression of MRP1
was 41% higher (GMR 1.41) in CD4 cells than in all peripheral blood mononuclear cells
(PBMCs).[7]
Darunavir is metabolized almost exclusively by the hepatic CYP3A4 enzyme.[8] Three
major metabolites of darunavir have been identified, all of which demonstrate at least 90%
less activity against wild-type HIV strains in comparison with darunavir. The darunavir
metabolite M19 forms by carbamate hydrolysis, metabolite M23 forms through aliphatic
hydroxylation, and metabolite M29 forms through aromatic hydroxylation. Three minor
darunavir metabolites have also been identified: M27 and M28 both form by alicyclic
hydroxylation and metabolite M6 forms through an unspecified pathway.[9]
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In human liver microsomes, darunavir inhibits the activity of CYP1A2, CYP2C9, CYP2C19
and CYP2D6.[10] In human hepatocytes, and in human subjects, darunavir induces
CYP3A4 activity. As a CYP3A4 substrate, darunavir also demonstrates competitive
inhibition of CYP3A4, yielding an inhibitory constant (Ki) value of 0.40 μmol/L (0.22 μg/
mL), which is within the range of clinical relevance. When darunavir is administered with
other CYP3A4 inhibitors (such as ritonavir), the net result is inhibition of CYP3A4 activity.
[10] Since darunavir’s Ki values for CYP2B6, CYP2C9, CYP2C19 and CYP2D6 are at least
60-fold higher than for CYP3A4, there is less potential for clinically relevant drug-drug
interactions through these enzymes.[9]
1.1.2 Pharmacokinetics—The absolute bioavailability of a 600 mg dose of darunavir is
37%. The addition of 100 mg of ritonavir increases the bioavailability to 82%. Owing to an
overall net inhibition of CYP3A4 and P-glycoprotein activity, coadministration of ritonavir
with darunavir results in a 14-fold increase in the darunavir area under the plasma
concentration-time curve (AUC) compared with administration of darunavir alone.[11]
In healthy volunteers, the median terminal elimination half-life is 15 (range 12.7–16.4)
hours.[4] In a study of a single 150 mg intravenous dose administered after 2 days of oral
ritonavir given 100 mg twice daily, the mean volume of distribution was 131 L.[2]
Pharmacokinetic parameters for darunavir obtained from 119 HIV-positive participants
included a median steady-state AUC over a 12-hour dosing interval (AUC12) of 61 668
(range 33 857–106 490) ng • h/mL and a median trough plasma concentration (Ctrough) of
3539 (range 1255–7368) ng/mL.[1]
Food increases the bioavailability of darunavir when coadministered with ritonavir by
approximately 30%, regardless of the composition of the meal.[12] Most of darunavir
(81.7%) is eliminated through faeces and 12.2% is eliminated through urine. The proportion
of unchanged darunavir eliminated in the faeces is 6.8% when administered alone and
41.2% when administered with ritonavir.[11]
1.1.3 Drug-Drug Interactions—Significant drug-drug interactions occur between
darunavir/ritonavir and certain other antiretrovirals and anti-infectives, HMG Co-A
reductase inhibitors, phosphodiesterase inhibitors, oral contraceptives and selective
serotonin reuptake inhibitors (SSRIs). Many of these interactions predictably occurred
through inhibition or induction of CYP3A4,[13] although some were unexpected.
Darunavir/Ritonavir and Protease Inhibitors: A 14-day evaluation in healthy subjects
coadministered darunavir/ritonavir 400 mg/100 mg with saquinavir 1000 mg in hard-gel
capsule formulation observed a reduction in darunavir exposure. The darunavir AUC12,
peak plasma concentration (Cmax) and minimum plasma concentration (Cmin) decreased by a
mean of 26%, 17% and 42%, respectively. Saquinavir exposure also slightly decreased: the
AUC12 and Cmax by 6% and the Cmin by 18%. Additionally, the combined administration of
darunavir, ritonavir and saquinavir was associated with an increased incidence of adverse
events and trial discontinuations.[14] Because of these observations, it is recommended that
saquinavir and darunavir not be administered together.
Two studies in healthy subjects investigated dosing strategies to overcome a decline in
darunavir exposure when combined with lopinavir/ritonavir. In one study, darunavir/
ritonavir was administered at 1200 mg/100 mg twice daily in combination with standard
lopinavir/ritonavir 400 mg/100 mg twice daily. In the second study, darunavir/ritonavir was
administered at 1200 mg/100 mg twice daily in combination with increased lopinavir/
ritonavir 533 mg/133 mg twice daily. Both strategies failed to prevent a decrease in
darunavir exposure. When the darunavir dose was doubled, the AUC12, Cmax and Cmin
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decreased by 38%, 21% and 51%, respectively. When the darunavir dose was doubled and
the lopinavir/ritonavir dose was increased, the darunavir AUC12, Cmax and Cmin decreased
by 41%, 21% and 55%, respectively. Lopinavir exposure was minimally influenced in both
trials (~9% increase in the AUC12). In contrast to the saquinavir investigations, no increases
in adverse events were reported with this combination of protease inhibitors. However,
based on the pharmacokinetic interaction, coadministration of darunavir/ritonavir with
lopinavir is not recommended.[15]
The interaction between indinavir and darunavir/ritonavir was studied using a dose of
darunavir that is lower than the currently licensed dose. Twice-daily administration of
indinavir 800 mg with darunavir/ritonavir 400 mg/100 mg increased both indinavir and
darunavir concentrations. The AUC and Cmin of indinavir increased by 23% and 125%,
respectively, while the AUC and Cmin of darunavir increased by 24% and 44%, respectively.
Although the appropriate dose of indinavir given in combination with darunavir/ritonavir
has not yet been established, in cases of intolerance to this combination, it is suggested that
the indinavir dose be reduced from 800 mg to 600 mg twice daily.[16]
The interaction between atazanavir and darunavir/ritonavir was also studied using a lower
than currently licensed dose of darunavir. Coadministration of atazanavir 300 mg once daily
with darunavir/ritonavir 400 mg/100 mg twice daily had no significant effect upon the AUC
and Cmin of either atazanavir or darunavir in a study of 13 healthy subjects. The Cmax, AUC
and Cmin of darunavir increased by only 2%, 3% and 1%, respectively. Compared with
atazanavir exposure when atazanavir/ritonavir was given alone, the Cmax decreased by a
mean of 11%, the AUC increased by 8% and the Cmin increased by 52%. Based on these
results, no adjustment in dose is considered necessary when atazanavir is administered with
darunavir/ritonavir.[16]
Darunavir/Ritonavir and Entry Inhibitors: Since maraviroc is a CYP3A4 substrate (see
section 3.1 for more details), concomitant administration with darunavir/ritonavir was
predicted to increase maraviroc exposure. Therefore, in a 10-day, two-way crossover drug
interaction study in healthy subjects, a 50% lower dose than the standard recommended dose
of maraviroc was used. When administered at 150 mg twice daily in combination with
darunavir/ritonavir or placebo, the AUC12 and Cmax of maraviroc were 2.3- to 4-fold higher
with darunavir/ritonavir than with placebo. Darunavir/ritonavir exposures were not
significantly altered. These results are consistent with findings from other studies[17,18]
administering maraviroc with ritonavir-boosted protease inhibitors.[19] Thus, when
coadministered with darunavir/ritonavir, the maraviroc dosage should be reduced by 50% to
150 mg twice daily.
A combination of twice-daily therapy with 90 mg of the fusion inhibitor enfuvirtide and
standard darunavir/ritonavir dosage has been studied in HIV-infected patients. No difference
was observed between the pharmacokinetic parameters of darunavir in the presence of
enfuvirtide and the pharmacokinetic parameters of darunavir administered alone. The effects
of darunavir/ritonavir on enfuvirtide have not been investigated.[20,21]
Darunavir/Ritonavir and Reverse Transcriptase Inhibitors: No dose adjustment is
warranted when darunavir is coadministered with nevirapine, tenofovir and etravirine. The
combination of darunavir with efavirenz should be used with caution.[8]
Nevirapine is a substrate and inducer of CYP3A4 enzyme activity. When darunavir/ritonavir
400 mg/100 mg was added to a stable antiretroviral regimen that contained nevirapine 200
mg twice daily, in a study of HIV-positive individuals, the combination resulted in a 24%
increase in the mean AUC12 of darunavir, a 40% increase in the mean Cmax and no influence
Brown et al. Page 4













on the Cmin. This combination resulted in increases in the nevirapine AUC12 and Cmin (by
27% and 47%, respectively), while no significant effect on the Cmax was observed. Based on
these results, no dose adjustment is necessary in the coadministration of darunavir/ritonavir
with nevirapine.[22]
A modest interaction has been observed with the coadministration of darunavir/ritonavir 300
mg/100 mg and tenofovir 300 mg. The pharmacokinetic parameters of this combination
were evaluated in a randomized, crossover study in 12 healthy subjects. When administered
with darunavir/ritonavir, the tenofovir AUC from 0 to 24 hours (AUC24), Cmax and Cmin
increased by a mean of 22%, 24% and 37%, respectively. When administered with
tenofovir, the darunavir AUC12, Cmax and Cmin were increased by a mean of 21%, 16% and
24%, respectively. Since these are only modest increases with no observed increase in
adverse events, no dose adjustment is necessary with this combination.[23]
Etravirine is a new NNRTI recently approved by the FDA. The pharmacokinetic interaction
between etravirine (100 or 200 mg twice daily, phase III formulation) and darunavir/
ritonavir (600 mg/100 mg twice daily) has been investigated in 23 healthy subjects.
Coadministration of etravirine 100 mg with darunavir/ritonavir decreased the etravirine
AUC12, Cmax and Cmin by a mean of 37%, 32% and 49%, respectively. Increasing the dose
of etravirine to 200 mg (the dose approved by the FDA) resulted in increases in the
etravirine AUC12, Cmax and Cmin by a mean of 80%, 81% and 67%, respectively, compared
with etravirine 100 mg given alone.
Compared with the observed exposure of darunavir administered alone, no significant
change in darunavir exposure occurred when darunavir was given with etravirine in studies
of HIV-infected patients.[24] Phase III trials of etravirine indicate that safe and effective
etravirine exposures are achieved when etravirine is administered in combination with
darunavir and ritonavir.[25] Thus, etravirine can be given in combination with darunavir/
ritonavir at the approved dose of 200 mg twice daily without any dose adjustments.[26]
Since darunavir/ritonavir inhibits CYP3A4 and efavirenz induces CYP3A4, a decrease in
darunavir exposure and an increase in efavirenz exposure would be predicted for these drugs
when administered concomitantly. This was confirmed in a study in healthy subjects with
the combination of darunavir/ritonavir 300 mg/100 mg given twice daily and efavirenz 600
mg given once daily. With this combination, the Cmin and Cmax of efavirenz increased by a
mean of 15% to 17%, respectively, while the AUC24 increased by 21%. Darunavir exposure
decreased with this combination: the Cmin by 31%, the Cmax by 15% and the AUC12 by
13%.[27] The combination of darunavir with efavirenz should be used with caution. No dose
adjustment is recommended for this combination, but clinical monitoring for toxicity
associated with increased exposure to efavirenz should be considered.
Darunavir/Ritonavir and HMG-CoA Reductase Inhibitors: Atorvastatin is an HMG-
CoA reductase inhibitor commonly used by HIV-infected patients for the management of
hyperlipidaemia. Atorvastatin is >98% bound to plasma proteins and is extensively
metabolized by CYP3A4 to active metabolites, which accounts for ~70% of HMG-CoA
reductase inhibitory activity.[28] In a pharmacokinetic study that expected an inhibitory
effect of darunavir/ritonavir on the metabolism of atorvastatin, darunavir/ritonavir 300 mg/
100 mg given twice daily was combined with atorvastatin 10 mg given daily to ten healthy
subjects. The pharmacokinetics of 40 mg of atorvastatin administered alone were compared
with the pharmacokinetics of 10 mg of atorvastatin administered daily and coadministered
with darunavir/ritonavir 300 mg/100 mg twice daily (n = 15 healthy subjects). The 10 mg
dose of atorvastatin administered with darunavir/ritonavir had an AUC24 that was only 15%
lower than that of the standard 40 mg dose of atorvastatin administered alone. Atorvastatin
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did not significantly affect the pharmacokinetics of darunavir/ritonavir. Therefore, it is
recommended that atorvastatin 10 mg once daily be utilized by patients receiving darunavir/
ritonavir to provide atorvastatin exposures similar to 40 mg when given alone.[29]
A study of 14 healthy subjects given pravastatin 40 mg with or without darunavir/ritonavir
found a significant increase in pravastatin exposures. Darunavir/ritonavir increased the Cmax
of pravastatin by an average of 63% (from a mean ± SD of 50.9 ± 67.6 to 86.9 ± 88.4 ng/
mL), the AUC24 by 81% (from 92.0 ± 86.4 to 175 ± 159 ng • h/mL) and the time to reach
the maximum concentration (tmax) by 50% (from 1.0 to 1.5 hours). Therefore, it is
recommended that pravastatin be initiated at the lowest possible dose in patients receiving
darunavir/ritonavir, and then increased gradually with careful monitoring.[30]
Darunavir/Ritonavir and Oral Contraceptives: When administered concurrently with
darunavir/ritonavir, hormonal contraceptive concentrations decline significantly. When
darunavir/ritonavir 600 mg/100 mg twice daily was administered in combination with daily
ethinylestradiol 0.035 mg and norethisterone (norethindrone) 1.0 mg (Ortho-Novum® 1/35)
in 19 HIV-infected women, the mean ethinylestradiol AUC24, Cmax and Cmin declined 44%,
32% and 62%, respectively. The mean AUC24, Cmax and Cmin of norethisterone declined
14%, 10% and 30%, respectively. Darunavir/ritonavir concentrations were not significantly
altered. Pharmacodynamic analyses of the serum concentrations of progesterone, luteinizing
hormone and follicle-stimulating hormone showed a lesser suppression of hormone
concentrations when darunavir/ritonavir was administered in conjunction with Ortho-
Novum® 1/35 than with administration of Ortho-Novum® 1/35 alone. These results suggest
that oral contraceptives may have reduced efficacy when administered with darunavir/
ritonavir.[31]
Darunavir/Ritonavir and Phosphodiesterase 5 Inhibitors: Sildenafil, vardenafil and
tadalafil are approved for the treatment of erectile dysfunction. These compounds are
predominantly metabolized by CYP3A4 and have strong recommendations for dose
reduction when given concurrently with other protease inhibitors.[32] The effects of
darunavir/ritonavir 400 mg/100 mg administered twice daily to steady state on the
pharmacokinetics of a single 25 mg dose of sildenafil were examined in 16 healthy male
subjects. The sildenafil Cmax decreased by 38% when sildenafil 25mg was coadministered
with darunavir/ritonavir, compared with when sildenafil 100mg was administered alone.
Darunavir plasma concentrations were not affected by this single dose. Therefore, a dose-
reduction recommendation for coadministration of phosphodiesterase 5 inhibitors with
darunavir/ritonavir is as follows: a single dose of sildenafil not exceeding 25mg within a 48-
hour time period, a single dose of vardenafil not exceeding 2.5mg within a 72-hour time
period and a single dose of tadalafil not exceeding 10mg within a 72-hour time period.[1]
Darunavir/Ritonavir and Selective Serotonin Reuptake Inhibitors: SSRIs are commonly
used in HIV-infected patients. Sertraline is primarily metabolized by CYP3A4 and
paroxetine is metabolized by CYP2D6. Drug-drug interactions between darunavir/ritonavir,
paroxetine and sertraline were investigated in a randomized, multiple-dose, crossover study
in 36 healthy subjects. Combined administration of darunavir/ritonavir 400 mg/100 mg
twice daily with either paroxetine 20 mg once daily or sertraline 50 mg once daily were
compared with the administration of these drugs alone. The paroxetine AUC12, Cmax and
Cmin decreased by a mean of 39%, 36% and 37%, respectively, while the fraction of
unbound (free) paroxetine increased by 25–35%. The sertraline AUC12, Cmax and Cmin
decreased by a mean of 49%, 44% and 49%, respectively, while the fraction of unbound
sertraline was not altered. Darunavir/ritonavir exposure was not significantly altered, and the
drug combinations were well tolerated.[33] Since the exact correlation between the SSRI
concentration and clinical response has not been defined, the clinical significance of the
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reduction in exposure is unknown. No empirical dose adjustment for paroxetine or sertraline
is currently recommended, although closely monitored dose titration may be warranted.
Darunavir/Ritonavir and Anti-Infectives: Rifabutin is both an inducer and a substrate of
CYP3A enzymes. Although no data are available for this interaction, coadministration of
darunavir/ritonavir is expected to increase rifabutin concentrations and decrease darunavir
concentrations, similarly to other ritonavir-boosted protease inhibitors. If coadministration is
necessary, it is suggested that rifabutin be administered 150 mg every other day or three
times weekly.[1]
Rifampicin (rifampin) is a potent inducer of CYP3A4 enzyme activity. Coadministration of
rifampicin with most protease inhibitors significantly decreases their plasma concentrations.
Thus, it is anticipated that coadministration of darunavir with rifampicin will cause a
significant decrease in darunavir plasma concentrations. No data are currently available on
the pharmacokinetics of darunavir in the presence of rifampicin, but coadministration of
these two agents is not recommended.[1]
Clarithromycin is a macrolide antibacterial agent indicated for prophylaxis and treatment of
Mycobacterium avium complex. Clarithromycin is also commonly used to treat pharyngitis,
tonsillitis and upper respiratory infections such as Chlamydia pneumoniae and
Streptococcus pneumoniae.[34] The primary and active metabolite of clarithromycin, 14-
hydroxy-clarithromycin, is produced through CYP3A-mediated oxidation, N-demethylation,
and hydroxylation.[35] Clarithromycin inhibits CYP3A enzyme activity and thus has the
potential for significant interaction with protease inhibitors. Although no significant
interaction has been observed between clarithromycin and the overall exposure of ritonavir
in plasma, ritonavir increases the exposure of clarithromycin by 77% and extensively
inhibits the formation of 14-hydroxy-clarithromycin.[36] The pharmacokinetics of the
coadministration of darunavir/ritonavir 400 mg/100 mg twice daily and clarithromycin 500
mg twice daily were examined in a three-way crossover study in 18 healthy subjects.
Pharmacokinetic assessments were performed after 7 days. The AUC12 and Cmax of
darunavir decreased by 17% and 13%, respectively. The least square mean AUC ratio of
darunavir administered alone compared with coadministration with clarithromycin was 0.87
(90% CI 0.75, 1.01). The least square mean ratio for the Cmax of darunavir administered
alone compared with coadministration with clarithromycin was 0.83 (90% CI 0.72, 0.96).
The AUC12 and Cmax of clarithromycin increased by 57% and 26%, respectively. The least
square mean AUC ratio of clarithromycin administered alone compared with
coadministration with darunavir was 1.57 (90% CI 1.35, 1.84). The least square mean ratio
for the Cmax of clarithromycin administered alone compared with coadministration with
darunavir was 1.26 (90% CI 1.03, 1.54). All concentrations of 14-hydroxy-clarithromycin
were below the lower limit of quantification (50 ng/mL).[17] Similar variations in the
pharmacokinetics of clarithromycin have been reported when clarithromycin was
administered in conjunction with other protease inhibitors, and these variations have had
little effect upon clinical outcome.[36-38] Since it is unlikely that the observed changes in
exposure will have clinical significance, no dose adjustment is required for darunavir or
clarithromycin in patients with normal renal function. A 50% dose reduction is
recommended for clarithromycin when coadministered with darunavir for individuals with
creatinine clearance of 30–60 mL/min. A 75% clarithromycin dose reduction is
recommended for individuals with creatinine clearance of <30 mL/min.[1]
Ketoconazole is both a substrate and an inhibitor of CYP3A4. A study in 15 healthy subjects
demonstrated that the combination of twice-daily darunavir/ritonavir 400 mg/100 mg and
ketoconazole 200 mg increased the darunavir AUC12 by 42%, the Cmax by 21% and the
Cmin by 73%. The mean AUC12, Cmax and Cmin of ketoconazole increased by 212%, 111%
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and 868%, respectively. Based on these data, it is recommended that ketoconazole should
not be given at doses greater than 200 mg once daily when combined with darunavir/
ritonavir. Although there are no data, the effects on itraconazole are expected to be similar,
and thus a maximum daily dose of 200 mg is also recommended.[39] No data currently exist
for the interaction between fluconazole and darunavir/ritonavir, although a clinical trial to
investigate these effects is currently under way. Given that fluconazole is a moderate
inhibitor of CYP3A4 enzyme activity, it is anticipated that plasma concentrations of
darunavir will increase, and a dose adjustment may be warranted.
Darunavir/Ritonavir and Acid-Reducing Agents: Gastrointestinal issues are common
among patients with HIV infection, and symptoms are often treated with acid-reducing
agents such as histamine H2-receptor antagonists (e.g. ranitidine) or proton pump inhibitors
(e.g. omeprazole). A multiple-dose study conducted in 16 healthy subjects compared the
pharmacokinetics of darunavir/ritonavir 400 mg/100 mg administered twice daily alone with
those in combination with ranitidine 150 mg twice daily or omeprazole 20 mg once daily.
Both ranitidine and omeprazole combinations were well tolerated and had no significant
effect on the pharmacokinetics of darunavir/ritonavir.[18]
2. Non-Nucleoside Reverse Transcriptase Inhibitors
Two new NNRTIs, one recently approved and the other in phase III clinical development,
have the potential for drug-drug interactions.
2.1 Etravirine
Etravirine (TMC125) is a second-generation NNRTI, which was recently approved by the
FDA for treatment-experienced patients with resistance to an NNRTI and other antiretroviral
agents (figure 1b). Etravirine, administered with or without a protease inhibitor or
enfuvirtide, is the first NNRTI to show clinical efficacy after 24 weeks in patients who have
demonstrated failure to respond to treatment with both a protease inhibitor and either
nevirapine or efavirenz.[40]
2.1.1 Pharmacology—The molecular weight of etravirine is 435.277 g/mol.[41]
Etravirine is a highly flexible, diaryl pyrimidine (DAPY) compound. Its structural flexibility
facilitates multiple binding complexes with both wild-type and mutant HIV strains, and thus
it has a high genetic barrier to the development of resistance.[42] Etravirine is highly bound
to human plasma proteins (>99%).[43] It is predominantly metabolized by CYP3A4,
CYP2C9 and CYP2C19, with minor glucuronidation.[44] Etravirine is a moderate inducer
of CYP3A4 and acyl glucuronides and a moderate inhibitor of CYP2C9 and CYP2C19.[45]
In vitro, etravirine metabolism is reduced by CYP3A4 inhibitors (i.e. indinavir) and is
increased by CYP3A4 inducers (i.e. nevirapine).[46] Renal elimination of etravirine is
minimal (<1.2%).[47]
Four formulations of etravirine have been investigated in pharmaceutical clinical trials:
TF002, TF034, TF035 and F060. Formulation TF035 was administered in most phase I and
phase II trials. Formulation F060, with enhanced bioavailability, was introduced in phase I–
IV clinical trials and is now commercially available.[45]
2.1.2 Pharmacokinetics—Etravirine has a 30- to 40-hour systemic half-life and a
distribution half-life of 3.9–5.4 hours.[47] The pharmacokinetic activity of etravirine
(TF035) was evaluated in two phase I, 7-day randomized, crossover studies in healthy
subjects. In the first study, 24 subjects (23 male, 1 female) were given etravirine 100 mg
twice daily, followed by etravirine 200 mg once daily. The least square mean ratios
comparing the pharmacokinetic parameters of once-daily and twice-daily administration
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were as follows: Cmin 0.74 (90% CI 0.69, 0.80), Cmax 1.42 (90% CI 1.34, 1.51) and AUC24
1.05 (90% CI 0.96, 1.14). In the second study, 41 subjects (22 male, 19 female) were given
etravirine 200 mg twice daily followed by etravirine 400 mg once daily. The least square
mean ratios comparing the pharmacokinetic parameters of once-daily and twice-daily
administration were as follows: Cmin 0.75 (90% CI 0.72, 0.79), Cmax 1.44 (90% CI 1.37,
1.50) and AUC24 1.03 (90% CI 1.00, 1.07). These results indicate that the Cmin of etravirine
is 25–26% lower with a once-daily dosage regimen than with a twice-daily regimen,
although equal daily administration results in similar overall daily systemic exposures.[48]
Etravirine exposure is reduced by 50% when administered in a fasted state.[47] The effect of
food and the type of meal on etravirine pharmacokinetics was investigated in a randomized,
open-label, three-way, crossover trial in two groups of 12 healthy subjects. A 100 mg dose
of etravirine (F060) was administered under the following five conditions: fasting, a
standardized low-fat breakfast, a snack, a high-fat meal and a high-fibre meal. Etravirine
pharmacokinetics were evaluated over 96 hours. When administered with a standardized
meal, the mean etravirine AUC12 values in the two groups were 1417 ± 1140 ng • h/mL and
1191 ± 700 ng • h/mL. The mean Cmax values in the two groups were 129 ± 64 ng/mL and
138 ± 61 ng/mL. Under fasting conditions, the Cmax and AUC12 of etravirine decreased by
44% and 51%, respectively. With a high-fibre meal, the etravirine Cmax and AUC12
decreased by 25%. Pharmacokinetic parameters were similar between the conditions in
which subjects were provided with breakfast and either a high-fat meal or a snack.
Therefore, it is recommended that etravirine should be administered with food.[49]
Finally, etravirine may be administered in patients with mild or moderate hepatic
impairment without dose adjustment. In a study comparing the exposures of 200 mg of
etravirine administered twice daily in HIV-negative volunteers with mild (Child-Pugh Class
A, n = 8) or moderate (Child-Pugh Class B, n = 8) hepatic impairment with healthy matched
controls (n = 16), etravirine exposures were comparable. After 8 days, the mean etravirine
AUC12 value among volunteers with mild hepatic impairment was 9546 ± 2630 ng • h/mL,
while the mean etravirine AUC12 value among matched healthy controls was 10650 ± 1688
ng • h/mL. After 8 days, the mean etravirine AUC12 value among volunteers with moderate
hepatic impairment was 7665 ± 4122 ng • h/mL, while the mean etravirine AUC12 value
among matched healthy controls was 8584 ± 1560 ng • h/mL.[50]
2.1.3 Drug-Drug Interactions—Drug-drug interaction data for etravirine are available
for selected nucleoside reverse transcriptase inhibitors (NRTIs), NNRTIs, protease inhibitors
and gastric acid-reducing agents. Sildenafil may require dose adjustment when administered
in conjunction with etravirine. Efavirenz, nevirapine, tipranavir/ritonavir, fosamprenavir/
ritonavir, atazanavir/ritonavir, unboosted protease inhibitors and clarithromycin should not
be coadministered.[25,46]
Etravirine and Protease Inhibitors: Etravirine decreases saquinavir exposure probably
through induction of CYP3A4 enzyme activity. A single dose of saquinavir 1200mg given
to 12 healthy subjects after 14 days of etravirine (TF035) 900 mg twice daily resulted in the
saquinavir AUC and Cmax being decreased by a mean of 52% (90% CI 20, 71) and 46%
(90% CI 14, 55), respectively.[51]
Full-dose ritonavir is known to both inhibit and induce CYP3A4 activity and to induce
glucuronidation.[52] In a study of 11 healthy subjects, a single dose of etravirine (TF035)
400 mg was administered after ritonavir 600 mg twice daily for 7 days. Ritonavir
significantly decreased the etravirine AUC12 by 46% (range 27–59%) and the Cmax by 32%
(range 15–45%).[53] The observed decrease in etravirine exposure when administered with
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full-dose ritonavir provides evidence for glucuronidation as a second metabolic pathway for
etravirine.[53] Full-dose ritonavir and etravirine should not be coadministered.[25]
When indinavir and etravirine are coadministered, indinavir concentrations decrease and
etravirine concentrations increase. Ten healthy subjects were given indinavir 800 mg three
times daily with etravirine (TF035) 1600 mg twice daily for 14 days. The GMRs for the
etravirine AUC12, Cmax and Cmin comparing etravirine administered with indinavir and
etravirine alone were 1.51 (90% CI 1.20, 1.90), 1.51 (90% CI 1.16, 1.97) and 1.52 (90% CI
1.20, 1.91), respectively. The GMRs for the indinavir AUC8, Cmax and Cmin comparing
etravirine administered with indinavir and indinavir alone were 0.54 (90% CI 0.46, 0.62),
0.72 (90% CI 0.58, 0.89) and 0.24 (90% CI 0.18, 0.34), respectively.[53] Based on these
data, indinavir and etravirine should not be combined.
Unexpected drug interactions can occur with ritonavir-boosted protease inhibitors.
Fosamprenavir alone has been shown to induce CYP3A4 enzyme activity, while low-dose
ritonavir is a potent CYP3A4 inhibitor.[54] In a two-way, open-label, pharmacokinetic drug
interaction study with eight HIV-infected patients, coadministration of etravirine,
fosamprenavir and ritonavir was investigated. All patients were taking a stable regimen of
fosamprenavir/ritonavir 700 mg/100 mg twice daily. Etravirine (TF035) 800 mg twice daily
was added to the regimen for 14 days. With this combination, the AUC12, Cmax and Cmin of
amprenavir increased by 69%, 62% and 77%, respectively. The pharmacokinetic parameters
of etravirine were similar to those observed in historical controls.[55] Coadministration of
etravirine and fosamprenavir/ritonavir should be avoided. If concomitant use is required,
patients should be monitored carefully for adverse events associated with increased
amprenavir exposure, including nausea, vomiting, paraesthesias, elevated liver enzymes and
neuropathy.[25]
Tipranavir administered without ritonavir induces CYP3A4 enzyme activity.[56] Tipranavir/
ritonavir has been found to potently inhibit hepatic and intestinal CYP3A4/5 enzyme
activity after a single dose and to moderately induce hepatic and intestinal CYP3A4/5
enzyme activity over time. However, the net effect is CYP3A4/5 inhibition once steady-state
conditions are achieved.[57] In a study of 24 healthy subjects, tipranavir/ritonavir 500 mg/
200 mg twice daily decreased the exposure of etravirine (TF035) 800 mg twice daily by
76%. The etravirine AUC12, Cmax and Cmin, administered with tipranavir/ritonavir, declined
by a mean of 76% (90% CI 67, 82), 71% (90% CI 60, 78) and 82% (90% CI 75, 87),
respectively. Etravirine slightly increased tipranavir exposure, with the AUC12, Cmax and
Cmin increasing by a mean of 18% (90% CI 3, 36), 14% (90% CI 2, 27) and 24% (90% CI
−4, 59). Ritonavir exposures were similarly increased. Owing to the clinically significant
decrease in etravirine exposure when administered with tipranavir/ritonavir, these two drugs
should not be used in combination.[58]
Dual-boosted protease inhibitor therapy, once a management strategy of interest, has now
fallen out of favour because of the complex drug interactions and lack of documented
benefit compared with single-boosted protease inhibitor therapy. The pharmacokinetic
influence of etravirine (TF035) 800 mg twice daily was evaluated in 15 HIV-infected
patients on a stable regimen of twice-daily lopinavir/ritonavir/saquinavir at varying dosages:
400 mg/100 mg/1000 mg (n = 6), 400 mg/100 mg/800 mg (n = 5), 400 mg/200 mg/800 mg
(n = 1) and 533 mg/133 mg/800 mg (n = 3). Pharmacokinetic treatment ratios comparing
drug concentrations on etravirine with those off etravirine were computed in a combined
analysis of subject data (n = 11) from all dosage conditions. When combined with etravirine,
the lopinavir AUC12, Cmax and Cmin were 82%, 84% and 76%, respectively, of those
without etravirine; the saquinavir AUC12, Cmax and Cmin were 87%, 85% and 87%,
respectively, of those without etravirine, and the ritonavir AUC12, Cmax and Cmin were 88%,
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89% and 87%, respectively, of those without etravirine. Statistically significant decreases
were noted only for the lopinavir Cmax (p = 0.03) and AUC12 (p = 0.04). However, with
these observed changes being relatively small (11–24%), clinical significance is unlikely.
No clinically significant changes were observed in the pharmacokinetic parameters of
saquinavir and ritonavir (p > 0.3).[59]
Etravirine and Reverse Transcriptase Inhibitors: Only the NRTI didanosine has been
evaluated in an interaction study with etravirine, with no clinically significant changes in the
pharmacokinetics of either drug. Fourteen healthy subjects were given etravirine (TF035)
800 mg twice daily with didanosine 400 mg once daily.[60] For etravirine, the GMRs for the
AUC12, Cmax and Cmin were 1.11 (90% CI 0.98, 1.24), 1.16 (90% CI 1.02, 1.32) and 1.04
(90% CI 0.93, 1.17), respectively. For didanosine, the GMRs for the AUC24 and Cmax were
0.99 (90% CI 0.79, 1.25) and 0.91 (90% CI 0.58, 1.42), respectively. These findings were
confirmed in a study evaluating staggered administration of etravirine and didanosine.[61]
Based on these data, no dose adjustments are recommended for this combination.
When administered with nevirapine or efavirenz, etravirine exposure significantly decreases.
In a 14-day study of five healthy subjects, nevirapine 200 mg twice daily reduced the
AUC12 and Cmax of a single dose of etravirine (TF035) 900 mg by 55% and 36%,
respectively.[51] In a larger study of 12 healthy subjects given efavirenz 600 mg once daily
for 14 days, etravirine exposure (the Cmax and AUC12) decreased by 18% and 40%,
respectively: the GMRs for the Cmax and AUC12 for a single dose of etravirine 900 mg were
0.83 (90% CI 0.73 0.93) and 0.59 (90% CI 0.52, 0.68), respectively.[53] Since nevirapine
and efavirenz are both substrates and inducers of CYP3A4/5 enzyme activity, it is
anticipated that coadministration of these drugs with etravirine will result in either
unchanged or reduced nevirapine and efavirenz exposures. Therefore, it is recommended
that these drugs not be given in combination.[25]
A study evaluating the pharmacokinetics and safety of etravirine administered once or twice
daily after multiple doses of efavirenz found that efavirenz-dependent CYP3A induction
persists for at least 14 days after efavirenz is stopped. Healthy volunteers (n = 24, 10
females) received etravirine 400 mg once daily or etravirine 200 mg twice daily for 14 days,
followed by 14 days of efavirenz 600 mg once daily. After this time, each subject received
their initial etravirine regimen for another 14 days. Full pharmacokinetic assessments before
and after the 14-day administration of efavirenz indicated that etravirine exposure decreased
in both treatment groups. The etravirine Cmax and AUC24 decreased by 22% and 32%,
respectively, in those receiving etravirine 400 mg once daily. For those who took etravirine
200 mg twice daily, the etravirine Cmax and AUC24 decreased by 19% and 26%,
respectively. Efavirenz concentrations were detectable in all subjects 7 days after the drug
was stopped. The decrease in etravirine exposure was not considered clinically significant,
and therefore no dosage adjustment is necessary when switching from efavirenz to
etravirine.[62]
Etravirine and Integrase Inhibitors: Elvitegravir and raltegravir are members of the
newest class of antiretroviral agents (see section 4), and they are metabolized by CYP3A4
(elvitegravir) and glucuronidase enzymes (elvitegravir and raltegravir). Elvitegravir is
currently administered with ritonavir. An investigation into the pharmacokinetic interaction
between elvitegravir/ritonavir 150 mg/100 mg once daily and etravirine (F060) 200 mg
twice daily was conducted in a study of 34 healthy subjects (17 male, 17 female). No
clinically relevant drug interactions were found between elvitegravir/ritonavir and etravirine.
[43]
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Similarly, there is no interaction between etravirine and raltegravir, as determined in a
crossover study of 19 healthy subjects. All subjects received raltegravir 400 mg and
etravirine (F060) 200 mg twice daily. Raltegravir minimally increased the AUC12, Cmax and
Cmin of etravirine by 10%, 4% and 17%, respectively. Etravirine decreased the AUC12,
Cmax and Cmin of raltegravir by 10%, 11% and 34%, respectively. The observed small
decreases in the pharmacokinetic parameters of raltegravir may stem from the induction of
glucuronidation by etravirine.[63]
Etravirine and Phosphodiesterase 5 Inhibitors: Fifteen healthy subjects were given a
single dose of sildenafil 50 mg after 13 days of etravirine (TF035) 800 mg twice daily.[44]
The mean decline in the sildenafil AUC12 was 57% (range 49–64%), suggesting that
etravirine induction of CYP3A4 reduced these concentrations. Therefore, it is advised that
the dose of sildenafil be increased and titrated according to the clinical effect when
coadministered with etravirine.
Etravirine and Selective Serotonin Reuptake Inhibitors: No dose adjustment is required
when etravirine and paroxetine are administered together. This interaction was studied in 16
healthy subjects given etravirine (TF035) 125 mg twice daily and paroxetine 20 mg once
daily. Minimal changes were observed in the pharmacokinetic parameters of both drugs.
Etravirine increased the AUC12 and Cmax of paroxetine by 3% and 6%, respectively.
Paroxetine increased the AUC12, Cmax and Cmin of etravirine by 1%, 5% and 7%,
respectively.[64]
Etravirine and Acid-Reducing Agents: Acid-reducing agents do not affect the
pharmacokinetics of etravirine to a clinically significant extent. In a study of 19 healthy
subjects (12 male, 7 female) given ranitidine 150 mg twice daily and a single dose of
etravirine (F060) 100 mg, no change was noted in the AUC12 (GMR 0.86; 90% CI 0.76,
0.97) or Cmax (GMR 0.94; 90% CI 0.75, 1.17) of etravirine. In a study of 19 healthy subjects
given omeprazole 40 mg once daily and a single dose of etravirine 100 mg, the AUC12 and
Cmax of etravirine increased by a mean of 41% (range 22–62%) and 17% (range 0–43%),
respectively.[65] This interaction is likely to be due to competitive inhibition of CYP2C19.
However, no dosage adjustment is required to accommodate this interaction.
Etravirine and Methadone: Methadone is a racemic mixture of two enantiomers, R-
methadone and S-methadone. S-methadone is pharmacologically inactive and is more
protein bound than R-methadone. R-methadone is pharmacologically active and displays a
greater mean plasma clearance, volume of distribution and mean elimination half-life than S-
methadone.[66] Methadone undergoes stereoselective hepatic metabolism primarily by
CYP2B6 and is also metabolized to a much lesser extent by CYP3A4.[67] In an open-label
study of 16 healthy male subjects on stable therapy with methadone, etravirine (F060) 100
mg was administered twice daily for 14 days. No clinically significant changes in
methadone exposure were observed. For R-methadone administered alone, the (mean ± SD)
Cmax was 222 ± 74 ng/mL and the AUC24 was 3807 ± 1301 ng • h/mL. After 14 days of
coadministration with 100 mg of etravirine twice daily, the Cmax of R-methadone was 228 ±
75 ng/mL and the AUC24 was 4038 ± 1309 ng • h/mL. For S-methadone administered alone,
the Cmax was 285 ± 103 ng/mL and the AUC24 was 4378 ± 1809 ng • h/mL. After 14 days
of the coadministration with 100 mg of etravirine twice daily, the Cmax of S-methadone was
264 ± 107 ng/mL and the AUC24 was 4029 ± 1834 ng • h/mL.[68]
No methadone withdrawal symptoms were observed. However, owing to the long
elimination half-life of methadone (7–59 hours), 14 days of therapy may not be of sufficient
duration to see an effect. Given these results, methadone dose adjustment is not necessary
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when coadministered with etravirine.[69] However, patients should be monitored for
withdrawal symptoms, and some patients may require a dose adjustment for methadone.[25]
Etravirine and Anti-Infectives: Clarithromycin inhibits CYP3A4 and is also converted by
CYP3A4 to its active metabolite, 14-hydroxy-clarithromycin. Etravirine is a substrate and
inducer of CYP3A4. Sixteen healthy male subjects participated in a randomized, open-label,
two-period, crossover trial in which the pharmacokinetics of etravirine 200 mg twice daily
were investigated alone and in combination with clarithromycin 500 mg twice daily. The
overall exposure of clarithromycin decreased in the presence of etravirine, while
concentrations of its metabolite, 14-hydroxy-clarithromycin, increased. Etravirine exposure
increased as well. The least square mean ratios for the pharmacokinetic parameters of
etravirine administered in combination with clarithromycin compared with etravirine alone
were AUC12 142% (90% CI 134, 150), Cmax 146% (90% CI 138, 156) and Cmin 146% (90%
CI 136, 158). The least square mean ratios for the pharmacokinetic parameters of 14-
hydroxy-clarithromycin when clarithromycin was administered in combination with
etravirine compared with etravirine alone were 121% (90% CI 105, 139) for the AUC12,
133% (90% CI 113, 156) for the Cmax and 105% (90% CI 90, 122) for the Cmin. Since 14-
hydroxy-clarithromycin has reduced activity against Mycobacterium avium complex, overall
activity against these organisms may be affected, and it is recommended that an alternative
agent, such as azithromycin, be considered.[70]
Etravirine and Antimycobacterials: Rifampicin, a potent inducer of CYP enzymes, is not
recommended for use with etravirine. Although no study has been conducted to specifically
investigate this interaction, it is likely that rifampicin will cause a significant decrease in
etravirine exposure.[25]
Both etravirine and rifabutin are substrates and inducers of CYP3A4 enzyme activity.
Rifabutin is commonly used as prophylaxis against Mycobacterium avium complex disease
in patients with advanced HIV disease. The 24-hour pharmacokinetic profiles of rifabutin
and its active metabolite, 25-O-desacetyl rifabutin, were examined in the presence of
etravirine. In this open-label, randomized, two-period, crossover trial, 16 healthy HIV-
negative subjects took rifabutin 300 mg once daily for 14 days followed by a 14-day
washout period. Following the washout period, each subject took etravirine (TF035) 800 mg
twice daily for 7 days followed by the combination of etravirine (TF035) 800 mg twice daily
and rifabutin 300 mg once daily for 14 days. In the 11 subjects included in the final analysis,
steady-state exposures of the etravirine concentration at 12 hours (C12) decreased by
approximately 37%. These effects are comparable to the decrease in etravirine when
coadministered with protease inhibitors. Steady-state exposures of rifabutin and 25-O-
desacetyl rifabutin at 24 hours postdose declined by approximately 17% when
coadministered with etravirine. Since these effects are not considered to be clinically
relevant, rifabutin may be administered in conjunction with etravirine without dose
adjustment.[71]
Etravirine and Azole Antifungals: Formal studies have not been conducted to elucidate
the effects of etravirine coadministration. Based upon known pharmacological properties of
etravirine and fluconazole, coadministration of these two agents is not expected to
significantly affect the exposure of either drug. Based upon the known properties of
ketoconazole and itraconazole, it is anticipated that if either agent is coadministered with
etravirine, the plasma concentrations of etravirine will decrease and the concentration of
either ketoconazole or itraconazole will decrease. These azole antifungals should be used
with caution in a patient who is taking etravirine and may require a dose adjustment,
depending on other drugs in the patient’s medication regimen.[25]
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Etravirine and HMG-CoA Reductase Inhibitors: Atorvastatin is primarily metabolized
by CYP3A4. Sixteen healthy subjects participated in a randomized, open-label, two-period,
crossover trial aimed at characterizing the pharmacokinetic parameters of etravirine (TF035)
800 mg twice daily in conjunction with atorvastatin 40 mg once daily. Etravirine exposure
was not affected by the presence of atorvastatin. The overall exposure of atorvastatin was
decreased by 37% in the presence of etravirine and a 27% increase in the exposure of
atorvastatin’s active metabolite, 2-hydroxy-atorvastatin, was observed. The least square
mean ratios for the pharmacokinetic parameters of atorvastatin administered in combination
with etravirine compared with atorvastatin alone were 63% (90% CI 58, 68) for the AUC24
and 104% (90% CI 84, 130) for the Cmax. The least square mean ratios for the
pharmacokinetic parameters of 2-hydroxy-atorvastatin when atorvastatin was administered
in combination with etravirine compared with atorvastatin alone were 127% (90% CI 119,
136) for the AUC24 and 175% (90% CI 160, 194) for the Cmax.[72]
2.2 Rilpivirine
Rilpivirine (TMC278) is a diarylpyrimidine compound with a higher genetic barrier to
resistance compared with currently approved NNRTIs. This high genetic barrier may be due
in part to its internal flexibility, enabling it to adjust its configuration in HIV-1 reverse
transcriptase in the presence of mutations (figure 1c).
2.2.1 Pharmacology—The molecular weight of rilpivirine is 366.4 g/mol.[73] The EC50
of rilpivirine against wild-type HIV-1 strains is 0.5 nmol/L (0.19 ng/mL). Rilpivirine is a
substrate of CYP3A4 enzyme activity and is slowly metabolized in human hepatocytes
through glutathione-dependent conjugative metabolism. Rilpivirine is over 99% bound to
human plasma proteins in a concentration-dependent manner.[74]
2.2.2 Pharmacokinetics—Pharmacokinetic parameters of rilpivirine were examined in a
randomized, double-blind, placebo-controlled, dose-ranging study in antiretroviral-naïve,
HIV-infected, men. Forty-seven patients received rilpivirine 25 to 150 mg as monotherapy
for 7 days. Full pharmacokinetic profiles completed on days 1 and 7 indicated that rilpivirine
was rapidly and well absorbed. The Cmax was attained by 3–4 hours, and the terminal
elimination half-life was estimated at 48 hours. After 7 days of a 50 mg dose, the mean ± SD
Cmax was 366 ± 125 ng/mL and the AUC24 was 4904 ± 1677 ng • h/mL. With a 100 mg
dose, the mean ± SD Cmax was 712 ± 351 ng/mL and the AUC24 was 9517 ± 4397 ng • h/
mL. Plasma concentrations increased with increasing doses of rilpivirine but were not dose
proportional. The 75 mg dose of rilpivirine was selected for development and is being
evaluated in phase III clinical trials. The plasma concentrations obtained with this dose are
above the target concentration of 13.5 ng/mL, the EC50 for wild-type virus adjusted for
protein binding.[75]
Rilpivirine should be administered with food. A study of rilpivirine 100 mg in 12 healthy
Caucasian men found that under fed conditions, the Cmax of rilpivirine is approximately
71% higher and the AUC from 0 to 48 hours (AUC48) is approximately 45% higher
compared with concentrations observed in a fasted state.[76]
2.2.3 Drug-Drug Interactions
Rilpivirine and Protease Inhibitors: Rilpivirine 150 mg once daily and darunavir/ritonavir
800 mg/100 mg once daily were coadministered in 16 healthy subjects. Darunavir/ritonavir
increased the AUC24, Cmax and Cmin of rilpivirine by 230%, 79% and 278%, respectively.
Rilpivirine had no clinically relevant effect on darunavir/ritonavir exposure. It is likely that
the increase in rilpivirine exposure is a result of CYP3A4 inhibition.[77] Specific dose
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recommendations for coadministration of rilpivirine and darunavir have yet to be
determined. No data combining rilpivirine with other protease inhibitors are available.
Rilpivirine and Reverse Transcriptase Inhibitors: Fifteen healthy subjects participated in
a study evaluating the steady-state interaction between once-daily administration of
rilpivirine 150 mg and tenofovir 300 mg. Tenofovir had no effect on the pharmacokinetics
of rilpivirine (a mean 2% increase in theAUC24, a 3%decrease in the Cmax and no change in
the Cmin). However, tenofovir exposure was increased in the presence of rilpivirine, with a
mean 24% increase in the AUC24, a 21% increase in the Cmax and a 21% increase in the
Cmin.[78] Although the effect of rilpivirine on tenofovir exposure is statistically significant,
it is not considered clinically relevant, and no dose modifications are recommended.
Rilpivirine and HMG-CoA Reductase Inhibitors: Atorvastatin 40 mg once daily had no
significant effect on the pharmacokinetics of rilpivirine (150 mg once daily) in a study of 16
healthy subjects. However, rilpivirine increased the Cmax of atorvastatin by 35%, but did not
change the AUC24 or Cmin. The AUC24 of the 2-hydroxy and 4-hydroxy metabolites of
atorvastatin also increased by 39% and 23%, respectively. Overall, the AUC of total HMG-
CoA reductase activity (calculated by the AUC sum of atorvastatin with the two
metabolites) increased by 20%.[79] Therefore, no dose reduction in atorvastatin is necessary
with concomitant rilpivirine therapy.
Rilpivirine and Anti-Infectives: The pharmacological effect of administration of rilpivirine
and anti-infectives has yet to be determined in clinical studies.
Rilpivirine and Azole Antifungals: The pharmacokinetic interaction between rilpivirine
150 mg once daily and ketoconazole 400 mg once daily was examined in a study of 16
healthy subjects. In the presence of ketoconazole, the AUC24, Cmax and Cmin of rilpivirine
increased by a mean of 49%, 30% and 76%, respectively. In the presence of rilpivirine, the
AUC24, Cmax and Cmin of ketoconazole decreased by a mean of 24%, 15% and 66%.
Specific dosage recommendations for coadministration of these medications have yet to be
formulated, but it is clear that this should be diligently monitored.[80]
Rilpivirine and Antimycobacterials: Rifampicin, a potent inducer of CYP3A4, is not
recommended for use with rilpivirine. A study of the coadministration of rilpivirine and
rifampicin in 16 healthy, HIV-negative subjects found that the AUC and Cmin of rilpivirine
were reduced by 80% and 89%, respectively, over a 24-hour period in the presence of
rifampicin. Rifampicin exposure was not changed.[81]
Rilpivirine and Acid-Reducing Agents: Since the solubility of rilpivirine decreases in
solutions with increasing pH, coadministration of drugs that increase gastric pH may
influence its absorption. A randomized, single-dose, four-way, crossover trial was conducted
to examine the pharmacokinetic effect of coadministration of rilpivirine and famotidine, a
commonly used H2-receptor antagonist. Twenty-four healthy male subjects completed four
treatment conditions, each separated by a 14-day washout period. Rilpivirine 150 mg was
administered alone and with famotidine 40 mg given 2 hours before, 12 hours before or 4
hours after a single dose of rilpivirine 150 mg with food. Intragastric pH was measured for
24 hours, and the pharmacokinetics of famotidine and rilpivirine were assessed up to 24 and
168 hours after the dose, respectively. When famotidine was given 2 hours beforehand, the
rilpivirine Cmax and the AUC from time zero to infinity (AUC∞) were reduced by 85% and
76%, respectively, in comparison with when rilpivirine was administered alone. This
interaction is suspected to result from the reduced solubility of rilpivirine with increased
gastric pH levels. When famotidine was given 12 hours beforehand, or 4 hours afterwards,
rilpivirine pharmacokinetics were not significantly affected. Famotidine pharmacokinetics
Brown et al. Page 15













were not affected by rilpivirine with any dosing strategy. Based on these findings,
famotidine can be combined with rilpivirine, provided it is given 12 hours before or 4 hours
after the rilpivirine dose.[82]
3. Chemokine Receptor Antagonists
3.1 Maraviroc
Maraviroc is a first-in-class CCR5-receptor antagonist approved by the FDA in August 2007
for use in treatment-experienced patients with drug resistance to multiple antiretrovirals.
Maraviroc prevents HIV-1 entry by blocking coreceptor binding via reversible non-
competitive inhibition and preventing further fusion to host CD4+ cell membranes (figure
1d).
3.1.1 Pharmacology—The molecular weight of maraviroc is 513.67 g/mol.[83] The
geometric mean IC90 for wild-type HIV-1 is 2.0 nmol/L. This IC90 was determined in
PBMC replication assays using viral clades A, B, C, D, E, F, G, J and O, with geometric
means of the IC90 values ranging from 0.51 to 4.4 nmol/L. Maraviroc is approximately 75%
bound to albumin and α1-acid glycoprotein.[84]
Maraviroc is primarily metabolized by CYP3A4 and its metabolism is inhibited by
approximately 70% in vitro when combined with potent CYP3A4 inhibitors such as
ketoconazole. Metabolism of maraviroc is not altered in the presence of CYP2C9
(sulphaphenazole) or CYP2D6 (quinidine) inhibitors.[85] As the IC50 of maraviroc is
greater than 30 μmol/L, it has limited inhibitory potential for the following enzymes:
CYP3A4, CYP2B6, CYP2D6, CYP2C8, CYP2C9, CYP2C19 and CYP1A2.[85] In healthy
subjects, maraviroc does not affect the pharmacokinetics of cortisol or midazolam, two
CYP3A4 substrates. A dose-ranging study of maraviroc (25 mg twice daily to 600 mg once
daily) demonstrated no change in 6β-hydroxycortisol/cortisol urinary ratios in 51 healthy
subjects.[86] Maraviroc 300 mg twice daily for 7 days increased the AUC and Cmax of oral
midazolam by <20%, suggesting no clinically relevant interaction.[86,87]
Maraviroc also has high affinity for the efflux transporter P-glycoprotein (Michaelis-Menten
constant [Km] = 37 μmol/L). Caco-2 permeability studies demonstrated polarized transport
of maraviroc with an efflux ratio (basolateral → apical/apical → basolateral) of >10. This
high efflux ratio suggests that an inhibitor of efflux could significantly enhance the
absorption of maraviroc. For example, digoxin has also been reported to have an efflux ratio
of 10, and this ratio is reduced in the presence of known P-glycoprotein inhibitors such as
verapamil (50%) and CP-100356 (75%). P-glycoprotein inhibitors, therefore, would have
the potential to increase the absorption of maraviroc.[88]
3.1.2 Pharmacokinetics—Largely owing to enterocyte metabolism by CYP3A4 and
efflux by P-glycoprotein, the dose-dependent bioavailability of maraviroc is 23–33%.
[89-91] In healthy subjects, the volume of distribution of maraviroc is 2.8 L/kg, and
apparent oral clearance is 10.5 mL/min/kg. The tmax ranges from 0.5 to 4 hours and the
terminal elimination half-life from 14 to 18 hours. The pharmacokinetic parameters in HIV-
infected patients are similar to those in healthy subjects. In addition to hepatic metabolism,
renal clearance accounts for approximately 20–25% of the elimination of maraviroc.
[89,90,92,93]
No sex or ethnicity (Caucasian vs Asian males) differences have been found in the
pharmacokinetics of maraviroc.[90,94] In patients with mild and moderate liver impairment
(Child-Pugh class A and B, respectively), the single-dose maraviroc AUC increased by 25%
and 46%, and the Cmax was increased by 11% and 32%, respectively. However, it is unlikely
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that these changes will warrant an adjustment in dosage.[95] Caution is advised for using
maraviroc in mild or moderate liver impairment. Pharmacokinetic evaluations have not yet
been conducted in patients with severe hepatic impairment or renal impairment, or in
pregnant, elderly or paediatric populations.[90]
Compared with the fasted state, high-fat meals reduce maraviroc exposure by 33%, and low-
fat meals reduce maraviroc exposure by 20%. However, this does not appear to significantly
affect antiviral activity, as no diet restrictions were made in phase III trials demonstrating
safety and efficacy.[89,90]
3.1.3 Drug-Drug Interactions—As maraviroc is metabolized byCYP3A4 and
transported by P-glycoprotein, dosage adjustment is required when CYP3A4 and/or P-
glycoprotein inhibitors or inducers are administered concomitantly. The maraviroc dose
should be reduced when combined with lopinavir, saquinavir, atazanavir and
ritonavirboosted elvitegravir, and increased when combined with efavirenz and etravirine.
The investigators for the following drug interaction studies did not report the effect of
maraviroc on the concomitant regimen unless indicated otherwise.
Maraviroc and Protease Inhibitors: In an investigation of maraviroc pharmacokinetics in
five HIV-infected subjects taking lopinavir/ritonavir 400 mg/100 mg twice daily, stavudine
40 mg twice daily, and lamivudine 150 mg twice daily, a single dose of maraviroc 300 mg
was administered. Comparing the pharmacokinetic data with the day 1 data from a historic
control of HIV-infected subjects, the maraviroc GMRs for the AUC12 and Cmax were 2.65
(90% CI 1.61, 4.35) and 1.80 (90% CI 1.03, 3.14). Therefore, a dose reduction strategy of
maraviroc to 150 mg twice daily is necessary when administered with lopinavir/ritonavir.
[96,97]
In 12 healthy male subjects, maraviroc 100 mg given twice daily combined with saquinavir
1200 mg three times daily yielded maraviroc GMRs for the AUC12 and Cmax of 4.25 (90%
CI 3.47, 5.19) and 3.32 (90% CI 2.45, 4.49), respectively.[98,99] Therefore, maraviroc
dosing should be reduced from 300 mg twice daily to 150 mg twice daily in combination
with unboosted saquinavir.
Healthy subjects were recruited to study the combined effects of CYP3A4 inhibitors and
inducers on the pharmacokinetics of maraviroc. The combination of maraviroc 300 mg twice
daily with lopinavir/ritonavir 400 mg/100 mg twice daily increased maraviroc exposure in
11 subjects: the GMRs for the maraviroc AUC12 and Cmax were 3.95 (90% CI 3.43, 4.56)
and 1.97 (90% CI 1.66, 2.34), respectively. When efavirenz 600 mg once daily was added to
this regimen, the GMRs for the maraviroc AUC12 and Cmax were 2.53 (90% CI 2.24, 2.87)
and 1.25 (90% CI 1.01, 1.55), respectively. The combination of maraviroc 100 mg twice
daily with saquinavir/ritonavir 1000 mg/100 mg twice daily increased maraviroc exposure in
healthy subjects: the maraviroc GMRs for the AUC12 and Cmax were 9.77 (90% CI 7.87,
12.14) and 4.78 (90% CI 3.41, 6.71), respectively. When efavirenz 600 mg was added to this
regimen, the maraviroc GMRs for the AUC12 and Cmax were 5.00 (90% CI 4.26, 5.87) and
2.26 (90% CI 1.64, 3.11), respectively.[90,100,101] Therefore, the maraviroc dose should be
reduced when combined with lopinavir/ritonavir or saquinavir/ritonavir, including regimens
that contain efavirenz.
A dose-adjustment trial demonstrated that a 75% reduction (from 100 mg to 25 mg) in the
maraviroc dose with saquinavir/ritonavir still resulted in a 40% increase in the AUC
compared with maraviroc 100 mg twice daily alone. However, reducing the dose of
maraviroc to 25 mg resulted in a 40% reduction in the Cmax compared with maraviroc 100
mg alone. Since the smallest dosage size for maraviroc is 150 mg as an unscored, film-
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coated tablet (with no recommendations for splitting or crushing), and the dose-limiting
toxicities for maraviroc appear to be related to the Cmax rather than the AUC, reducing the
dose of maraviroc to 150 mg twice daily is reasonable. When combining maraviroc with
saquinavir/ritonavir, close monitoring of the adverse effects and toxicity of maraviroc is
advised.[99]
In a two-way crossover study with tipranavir/ritonavir 500 mg/200 mg twice daily,
maraviroc 150 mg twice daily resulted in GMRs for the AUC12 and Cmax of 1.02 (90% CI
0.85, 1.23) and 0.86 (90% CI 0.61, 1.21), respectively, suggesting no significant interaction.
[99,102] Thus, a standard dosage of maraviroc (300 mg twice daily) should be used when
coadministered with tipranavir/ritonavir.
The interaction between maraviroc and atazanavir with or without ritonavir was studied in
12 healthy subjects. Maraviroc 300 mg twice daily was given with either atazanavir 400 mg
once daily or atazanavir/ritonavir 300 mg/100 mg once daily. When combined with
atazanavir alone, the GMRs for the AUC12 and Cmax of maraviroc were 3.57 (90% CI 3.30,
3.87) and 2.09 (90% CI 1.72, 2.55), respectively, and with atazanavir/ritonavir they were
4.88 (90% CI 4.40, 5.41) and 2.67 (90% CI 2.32, 3.08), respectively.[90,99,103] Therefore,
the maraviroc dose should be reduced to 150 mg twice daily when combined with any
atazanavir therapy.
Maraviroc and Reverse Transcriptase Inhibitors: The effect of maraviroc 300 mg on
lamivudine (150 mg twice daily) or zidovudine (300 mg twice daily) was evaluated in 11
healthy subjects. The GMRs for the lamivudine AUC12 and Cmax were 1.14 (90% CI 0.984,
1.323) and 1.16 (90% CI 0.875, 1.542), respectively. The GMRs for the zidovudine AUC12
and Cmax were 0.98 (90% CI 0.79, 1.22) and 0.92 (90% CI 0.68, 1.24), respectively, for
zidovudine. Therefore, no dosage adjustment is required when maraviroc is combined with
zidovudine and lamivudine.[87,104]
To investigate the effects of efavirenz on maraviroc pharmacokinetics, 12 healthy subjects
were given maraviroc 100 mg twice daily with efavirenz 600 mg once daily. The AUC12
and Cmax GMRs for maraviroc during efavirenz therapy were 0.487 (90% CI 0.414, 0.573)
and 0.436 (90% CI 0.304, 0.624), respectively. When the dose of maraviroc was increased
to 200 mg twice daily, the GMRs for the AUC12 and Cmax were 1.09 (90% CI 0.868, 1.37)
and 1.16 (90% CI 0.774, 1.75), respectively. This study demonstrated that the effects of
enzyme induction on maraviroc pharmacokinetics can be overcome by doubling the dose.
[101,105]
In HIV-infected subjects, the GMRs for the maraviroc AUC12 and Cmax were 0.469 (90%
CI 0.303, 0.724) and 0.665 (90% CI 0.408, 1.09), respectively, for those taking efavirenz
with lamivudine/zidovudine (n = 8) and 0.483 (90% CI 0.313, 0.746) and 0.764 (90% CI
0.468, 1.25), respectively, for those taking efavirenz with didanosine/tenofovir (n = 8). The
maraviroc GMRs of the AUC12 and Cmax for those taking nevirapine (with lamivudine and
tenofovir) were 1.01 (90% CI 0.651, 1.55) and 1.54 (90% CI 0.943, 2.51), respectively.
These data confirm the interaction seen in healthy subjects, and the maraviroc dosage should
be increased to 600 mg twice daily when combined with efavirenz, but a standard dosage
can be used when combined with nevirapine.[96,97]
In a two-period crossover study of the effects of etravirine with or without darunavir/
ritonavir on the pharmacokinetics of maraviroc, healthy subjects were enrolled. Etravirine
was administered 200 mg twice daily, maraviroc 150 mg twice daily and darunavir/ritonavir
600 mg/100 mg twice daily. Etravirine alone decreased the maraviroc AUC12 and Cmax by
53% and 60%, respectively, while the combination of etravirine and darunavir/ritonavir
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increased the maraviroc AUC12 and Cmax by 210% and 77%, respectively.[106] Therefore,
an increase in the maraviroc dose is required when combined with etravirine alone, but it
may not be necessary if there are other components of the medication regimen that inhibit
maraviroc metabolism.
Maraviroc and Integrase Inhibitors: In a study of 36 healthy subjects, the combination of
elvitegravir/ritonavir 150 mg/100 mg with maraviroc 150 mg did not affect concentrations
of elvitegravir (the GMRs for the AUC12 and Cmax were 1.1 and 0.99, respectively) or
ritonavir (the GMRs for the AUC12 and Cmax were 0.98 and 0.92, respectively). However,
maraviroc concentrations increased: the GMRs for the AUC12 and Cmax were 2.86 (90% CI
2.33, 3.51) and 2.15 (90% CI 1.71, 2.69), respectively.[107] The combination of ritonavir-
boosted elvitegravir will require a 50% dose reduction in maraviroc, which is similar to
other ritonavir-containing regimens.
A phase IV trial in 18 healthy subjects (16 males and 2 females, aged 18–55 years)
investigated the interaction between raltegravir and maraviroc. The following dosing
sequence was administered: raltegravir 400 mg twice daily was given for 3 days, followed
by a 2-day washout period, followed by maraviroc 300 mg twice daily given for 6 days,
followed by 3 days of maraviroc combined with raltegravir in the doses listed above. When
combined, the exposures of both drugs decreased. The maraviroc AUC12, Cmax and Cmin
GMRs were 0.86 (90% CI 0.80, 0.92), 0.79 (90% CI 0.67, 0.94) and 0.90 (90% CI 0.85,
0.96), respectively. The raltegravir AUC12, Cmax and Cmin GMRs were 0.63 (90% CI 0.44,
0.90), 0.67 (90% CI 0.41, 1.08) and 0.72 (90% CI 0.58, 0.91), respectively. Since the
reduction in maraviroc exposure was not considered to be clinically significant, no dosage
adjustment was recommended. The marked reduction in raltegravir exposure may be a cause
for concern, but no recommendations have yet been made in the US Department of Health
and Human Services (DHHS) treatment guidelines or the raltegravir prescribing
information. Given the large inter- and intrasubject variability in the pharmacokinetics of
raltegravir (three of the subjects had increased, rather than decreased, raltegravir exposure)
more studies are needed to understand this interaction.[101,108]
Maraviroc and Anti-Infectives: In 12 healthy male subjects, ketoconazole 400 mg once
daily in combination with maraviroc 100 mg twice daily produced a significant increase in
the maraviroc AUC12 and Cmax GMRs: 5.01 (90% CI 3.98, 6.29) and 3.38 (90% CI 2.38,
4.78), respectively. Because of the profound drug-drug interactions, these two compounds
should not be used together.[99]
The potent CYP3A enzyme-inducing capacity of rifampicin produces profound declines in
maraviroc exposure. In 12 healthy subjects given the combination of rifampicin 600 mg
once daily and maraviroc 100 mg twice daily, the maraviroc AUC12 and Cmax declined by
67% and 70%, respectively. Doubling the maraviroc dose to 200 mg twice daily overcame
the reduction in the AUC12 and Cmax seen with maraviroc 100 mg plus rifampicin 600 mg
once daily (the GMRs for the AUC12 and Cmax increased to 0.99 and 0.97, respectively).
[105] The combination of maraviroc, rifampicin and protease inhibitors was not studied.
However, it is recommended that this combination use the unadjusted dose of maraviroc.
[90,101]
No data have been generated for the combination of maraviroc and rifabutin. The induction
potential of rifabutin may decrease maraviroc exposures; however, rifabutin is considered
not to have a clinically significant effect on the pharmacokinetics of CYP substrates. The
DHHS treatment guidelines (November 2008) state that dosage adjustment is not warranted
in concomitant administration of maraviroc and rifabutin, but close monitoring of viral
response may be needed.[109]
Brown et al. Page 19













The effect of maraviroc on the pharmacokinetics of midazolam was studied in 12 healthy
subjects using a double-blind, placebo-controlled, crossover study design. Maraviroc was
administered at 300 mg twice daily for 7 days and midazolam was given as a single dose of
7.5 mg on day 7. The GMRs for the midazolam AUC12 and Cmax (maraviroc vs placebo)
were 1.18 (90% CI 1.04, 1.34) and 1.21 (90% CI 0.92, 1.60), respectively, showing that
maraviroc has a minor effect on midazolam pharmacokinetics, which is likely to be the case
for other substrates of CYP3A4. No dosage adjustment is required for concomitant
administration of maraviroc and midazolam.[87]
In 14 healthy female subjects, the effect of maraviroc on the pharmacokinetics of
ethinylestradiol and levonorgestrel was studied in a double-blind, placebo-controlled,
crossover study. Maraviroc was administered at 300 mg twice daily for 10 days with a single
dose on day 11, and ethinylestradiol 30 μg and levonorgestrel 150 μg were given once daily
on days 2–8. Comparing maraviroc plus ethinylestradiol/levonorgestrel with placebo plus
ethinylestradiol/levonorgestrel, the AUC24 and Cmax GMRs for ethinylestradiol were 0.996
(90% CI 0.945, 1.06) and 0.984 (90% CI 0.913, 1.06), respectively, and the AUC24 and
Cmax GMRs for levonorgestrel were 0.977 (90% CI 0.92, 1.04) and 1.00 (90% CI 0.93,
1.08), respectively. No dosage adjustment is necessary when combining maraviroc with
these oral contraceptives.[87]
3.2 Vicriviroc
Vicriviroc is a reversible noncompetitive CCR5 chemokine receptor inhibitor that is
currently in phase III studies (figure 1e).
3.2.1 Pharmacology—The molecular weight of vicriviroc is 533.63 g/mol. In human
plasma, approximately 84% is bound to proteins.[110] The in vitro binding affinity (Ki) of
vicriviroc for CCR5 receptors is 0.8 nmol/L. The geometric mean EC50 values for various
HIV-1 CCR5-tropic isolates range from 0.04 to 2.3 nmol/L, and EC90 values range from
0.45 to 18 nmol/L. Zidovudine, lamivudine, efavirenz, indinavir and enfuvirtide are reported
to have synergistic effects on HIV-1 replication with vicriviroc using a CCR5-tropic clinical
isolate in vitro.[110]
Using recombinant CYP enzymes, vicriviroc metabolites are formed by CYP3A4, CYP3A5
and CYP2C9. CYP3A4 is a major contributor to metabolite formation, and CYP3A5 and
CYP2C9 are minor contributors. This is confirmed by human liver microsomal incubations.
When combined with the potent CYP3A4 inhibitor ketoconazole, vicriviroc metabolism is
90% inhibited. Furthermore, incubation with an anti-CYP3A4/5 specific antibody inhibits
>80% of vicriviroc metabolism.[111]
Vicriviroc is not a significant substrate of P-glycoprotein. The efflux ratio obtained from
Caco-2 permeability studies is approximately 0.6, meaning that more vicriviroc is absorbed
than effluxed from the enterocyte.[112]
3.2.2 Pharmacokinetics—In HIV-infected individuals, the pharmacokinetic profile of
vicriviroc has been studied at doses of 10, 25 and 50 mg twice daily. Steady-state conditions
are reached in approximately 12 days, with a linear dose-pharmacokinetic relationship. The
reported median steady-state pharmacokinetic parameters using 50 mg twice daily include
an AUC12 of 2290 ng • h/mL, Cmax of 342 ng/mL, Cmin of 117 ng/mL, tmax of 1.5 hours,
elimination half-life of 28 hours, apparent oral clearance of 21 L/h and volume of
distribution of 778 L.[113]
A slight food effect is evident with vicriviroc absorption. A comparison of a high-fat meal
and fasting conditions in 20 healthy subjects given a single dose of vicriviroc 50 mg found a
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Cmax decrease of 58% (range 52–65%), although the relative oral bioavailability was 107%
(range 101–113%). Because exposure is minimally affected, as shown by the relative oral
bioavailability, vicriviroc can be administered without regard to food.[114]
3.2.3 Drug-Drug Interactions—Vicriviroc interactions have been evaluated with
selected NRTIs, efavirenz and multiple protease inhibitors. For the following drug
interactions, no data have been reported on the effect of vicriviroc on the concomitant
regimen.
Vicriviroc and Protease Inhibitors: In a study of 46 healthy subjects, the pharmacokinetic
profile of vicriviroc 10 mg given twice daily was evaluated in combination with ritonavir
100 mg once daily, 100 mg twice daily, 200 mg twice daily or 400 mg twice daily. Ritonavir
increased the vicriviroc AUC12 and Cmax by 469–585% and 301–395%, respectively.[115]
This demonstrated that regardless of the ritonavir dose, vicriviroc exposure was increased to
a similar extent. Dosage adjustment will not be necessary, because vicriviroc will require
boosting by ritonavir (30 mg/100 mg once daily).
The pharmacokinetics of vicriviroc 15 mg once daily in combination with ritonavir 100 mg
once or twice daily in 40 healthy subjects were compared with those of vicriviroc combined
with the following ritonavir-enhanced regimens: atazanavir/ritonavir 300 mg/100 mg once
daily (n= 8), indinavir/ritonavir 800 mg/100 mg twice daily (n = 8), fosamprenavir/ritonavir
700 mg/100 mg twice daily (n = 8), nelfinavir/ritonavir 1250 mg/100 mg twice daily (n = 8;
3 dropped out) and saquinavir/ritonavir 1000 mg/100 mg twice daily (n = 8). No clinically
significant changes were noted in vicriviroc exposure with any of the protease inhibitor
combinations. The GMRs for the AUC12 and Cmax of vicriviroc with atazanavir were 1.11
(90% CI 1.08, 1.15) and 1.1 (90% CI 1.0, 1.21), respectively; with indinavir were 1.03 (90%
CI 0.89, 1.19) and 0.93 (90% CI 0.82, 1.05), respectively; with fosamprenavir were 0.98
(90% CI 0.81, 1.18) and 1.0 (90% CI 0.81, 1.24), respectively; with nelfinavir were 0.96
(90% CI 0.86, 1.08) and 0.88 (90% CI 0.76, 1.03), respectively; and with saquinavir were
1.11 (90% CI 0.99, 1.24) and 1.18 (90% CI 1.08, 1.29), respectively.[116] Therefore, no
dosage adjustment is needed when vicriviroc is combined with these boosted protease
inhibitor regimens. Similarly, a study in 24 healthy subjects found the exposure of vicriviroc
combined with ritonavir to be similar to that of vicriviroc combined with lopinavir/ritonavir,
suggesting no vicriviroc dosage adjustment will be needed should these drugs be combined
during therapy.[117]
A study of the interaction between vicriviroc 15 mg and tipranavir/ritonavir 500 mg/200 mg
twice daily was evaluated in eight healthy subjects, and vicriviroc exposures were compared
with a dosage regimen of vicriviroc/ritonavir 15 mg/100 mg twice daily. No difference in
vicriviroc exposure was found.[118]
Vicriviroc and Reverse Transcriptase Inhibitors: No significant interactions occur
between vicriviroc (50 mg twice daily) and lamivudine (150 mg twice daily) or zidovudine
(300 mg twice daily). In 36 healthy subjects, the GMRs for the AUC12 and Cmax of
vicriviroc in combination with zidovudine/lamivudine compared with vicriviroc alone were
0.91 (90% 0.77, 1.09) and 0.92 (90% 0.77, 1.10), respectively. Similarly, the AUC12 and
Cmax GMRs for zidovudine were 0.93 (90% 0.76, 1.14) and 0.92 (90% 0.68, 1.25),
respectively, and the AUC12 and Cmax GMRs for lamivudine were 0.96 (90% 0.81, 1.13)
and 0.85 (90% 0.69, 1.05), respectively.[119] Additionally, no significant interaction was
seen in 24 healthy subjects when vicriviroc 10 mg twice daily was combined with tenofovir
300 mg once daily.[120]
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Efavirenz significantly induces the metabolism of vicriviroc. In 36 healthy subjects,
efavirenz 600 mg once daily for 14 days decreased the AUC24 and Cmax of vicriviroc 10 mg
once daily by a mean of 81% (90% CI 74, 86) and 67% (90% CI 56, 75), respectively. When
ritonavir 100 mg was added to the vicriviroc regimen once daily, the inductive effects were
attenuated. The vicriviroc AUC24 and Cmax increased by 384% (90% CI 279, 529) and
196% (90% CI 147, 261), respectively. Therefore, vicriviroc and efavirenz may be
administered together, provided that ritonavir is also utilized in the regimen.[121]
3.3 INCB 9471
INCB 9471 is a reversible noncompetitive CCR5 antagonist which has recently completed
phase IIa studies. This compound binds to CCR5 receptors slightly differently from other
CCR5 receptor antagonists, and its favourable pharmacokinetic profile allows once-daily
administration and no requirement for boosting (figure 1f).[122]
3.3.1 Pharmacology—The molecular weight of INCB 9471 is 559.67 g/mol. In vitro, the
mean IC90 of INCB 9471 for preventing infection ofPBMCs was 9.3 nmol/L. In assays
using the native ligand for chemokine receptors, INCB 9471 was shown to have high
receptor selectivity for CCR5, with an IC50 of 7.1 nmol/L. INCB 9471 is 84% bound to
plasma proteins.[123] The protein-binding corrected IC90 is 50–60 nmol/L.[124]
INCB 9471 is a weak inhibitor of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4
activity (IC50 values all >25 μmol/L). It was also reported that based on reporter gene assay
results, the drug is unlikely to induce CYP3A4.[124]
3.3.2 Pharmacokinetics—In a single dose-ranging study in 12 healthy subjects receiving
INCB 9471 2.5 mg to 300 mg, the Cmax ranged from 8.9 to 1300nmol/L, the tmax from 1.9
to 1.4 hours, the elimination half-life from 3.4 to 48.0 hours and the AUC∞ from 59 to 21
163 nmol • h/L.[124] In a repeat-dose study in 12 healthy subjects, the pharmacokinetics of
INCB 9471 50 mg twice daily, 100 mg twice daily, 150 mg once daily and 200 mg once
daily were assessed and exhibited a dose-linear relationship. The Cmax ranged from 437 to
1363 nmol/L, the tmax from 2.1 to 2.7 hours, the Cmin from 231 to 416 nmol/L and the AUC
during the dosage interval (AUCτ) from 3843 to 16 802 nmol • h/L. The elimination half-life
was approximately 42 to 56 hours. The Cmin for the 200 mg dose (416 nmol/L) was 8-fold
higher than the protein binding-adjusted IC90 in PBMCs.[124] Therefore, the 200 mg once-
daily dose is being studied in phase IIb investigations.
3.3.3 Drug-Drug Interactions—Minimal information is available on the
pharmacokinetic drug-drug interaction potential of INCB 9471. In one study in 12 healthy
subjects, INCB 9471 25 mg twice daily was combined with ritonavir 100 mg twice daily.
Compared with INCB 9471 alone, ritonavir increased the AUC12 and Cmax by 1300% and
55%, respectively.[125] Therefore, INCB 9471 will most likely require dose adjustment
when combined with boosted protease inhibitor regimens.
4. Integrase Inhibitors
4.1 Raltegravir
Raltegravir, also known as MK 0518, is an integrase strand transfer inhibitor from the
hydroxypyrimidine carboxamide class.[126] It is active against multidrug-resistant CCR5-
tropic and CXCR4-tropic HIV-1, and the drug has activity against HIV-2.[127] Raltegravir
blocks the ability of integrase to catalyse the stepwise process by which HIV-1 DNA is
inserted into host cell DNA (figure 1g).
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4.1.1 Pharmacology—The molecular weight of raltegravir is 482.507 g/mol. In 50%
human serum, the raltegravir IC95 (mean ± SD) is 31 ± 20 nmol/L. Raltegravir is
approximately 83% bound to human plasma proteins.[126]
Raltegravir is primarily metabolized in the liver through uridine diphosphate
glucuronosyltransferase (UGT) 1A1-mediated glucuronidation. A study investigating the
excretion of a 200 mg dose of raltegravir in eight healthy subjects estimated the fraction of
raltegravir metabolized by UGT1A1 to be 0.7.[128] Raltegravir is neither a potent inhibitor
nor an inducer of CYP enzymes or drug transporters and thus has reduced potential for
antiretroviral drug interactions. Based on these properties, raltegravir is not expected to alter
the pharmacokinetics of drugs that are substrates of CYP3A4, UGT1A1, UGT2B7 or P-
glycoprotein. Since raltegravir is not metabolized by CYP3A or transported by P-
glycoprotein, pharmacokinetic enhancement with low-dose ritonavir is not required to
achieve therapeutic concentrations.[126]
4.1.2 Pharmacokinetics—In a study of 24 healthy male subjects, raltegravir was rapidly
absorbed (tmax ~3 hours). The volume of distribution of raltegravir is approximately 6–7 L/
kg, the apparent oral clearance is 0.5 L/h/kg and the terminal elimination half-life is ~9
hours.[129] Bioavailability is estimated at 30%. A dose-ranging study in 35 antiretroviral-
naïve HIV-1-infected subjects given doses of raltegravir 100, 200, 400 and 600 mg twice
daily demonstrated that the geometric mean C12 in each dosage group exceeded the
estimated IC95 of 33 nmol/L.[130] A high-fat meal slows the rate of raltegravir absorption,
increasing the C12 by 750%, the AUC12 by 19% and the tmax by 7.3 hours and decreasing
the Cmax by 34%.[131]
Raltegravir is generally well tolerated in patients with moderate hepatic impairment or
severe renal insufficiency. These conditions have no clinically important effects upon the
pharmacokinetics of raltegravir, and no dose adjustment is required.[132]
4.1.3 Drug-Drug Interactions—Pharmacokinetic drug-drug interaction studies have
demonstrated clinically insignificant changes in raltegravir exposure when coadministered
with efavirenz, ritonavir, tenofovir[126] and tipranavir.[133]
Raltegravir and Protease Inhibitors: No adjustment in the dosage of raltegravir is
required for coadministration with ritonavir, atazanavir or tipranavir. In the presence of
ritonavir, the GMRs for the raltegravir AUC12, Cmax and C12 are 0.84, 0.99 and 0.76,
respectively. These results are not considered clinically significant.[134]
A study of the effects of atazanavir on the pharmacokinetics of raltegravir was conducted in
12 healthy subjects; the C12 values of raltegravir increased by 95% in the presence of
atazanavir compared with raltegravir administered alone.[131] Despite this pharmacological
change, the combination of atazanavir and raltegravir was not associated with any adverse
events, and no dose adjustment appears necessary.[126] In a study of 15 healthy subjects,
the combination of tipranavir and ritonavir decreased the C12 values of raltegravir by 55%.
[135] However, the C12 values were shown to span a 5-log range in the phase III
BENCHMRK studies.[136] As a result, the decrease associated with tipranavir/ritonavir
coadministration is not considered to be of clinical concern. Moreover, approximately 100
subjects received raltegravir in combination with tipranavir/ritonavir in the BENCHMRK
studies. Comparable efficacy was observed in this subgroup relative to those not receiving
tipranavir/ritonavir.[137] Taken together, these data indicate that tipranavir/ritonavir may be
coadministered with raltegravir without dose adjustment of raltegravir. Since raltegravir
concentrations may be decreased when administered in conjunction with tipranavir/ritonavir,
the therapeutic efficacy of raltegravir should be monitored closely.
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Raltegravir and Reverse Transcriptase Inhibitors: Since raltegravir is primarily
metabolized by glucuronidation and displays no inductive or inhibitory action on CYP
enzymes in vitro, raltegravir is not expected to affect the pharmacokinetic activity of
NNRTIs.
The interactions between raltegravir 400 mg twice daily and tenofovir 300 mg once daily
were examined in a three-period, open-label study in ten healthy subjects. When
coadministered with tenofovir, the GMRs for the AUC12, Cmax and C12 of raltegravir were
1.49 (90% CI 1.15, 1.94), 1.64 (90% CI 1.16, 2.32) and 1.03 (90% CI 0.73, 1.45),
respectively. For tenofovir, the GMRs for the AUC24, Cmax and C24 were 0.90 (90% CI
0.82, 0.99), 0.77 (90% CI 0.69, 0.85) and 0.87 (90% CI 0.74, 1.02), respectively. Since
tenofovir is primarily eliminated through both glomerular filtration and active tubular
secretion, these results indicate an expected lack of interaction between tenofovir and
raltegravir.[138]
The interaction between raltegravir/ritonavir and efavirenz was examined in 12 healthy
subjects. Coadministration of efavirenz 600 mg once daily with single doses of raltegravir
400 mg decreased the AUC and Cmax of raltegravir by 36% and the Cmin by 21%. The
observed reduction in raltegravir pharmacokinetics was not considered clinically
meaningful. Ritonavir dosing has marginal effects on raltegravir pharmacokinetics, as
determined by the C12, AUC1∞ and Cmax GMRs of 0.99 (90% CI 0.70, 1.40), 0.84 (90% CI
0.70, 1.01) and 0.76 (90% CI 0.55, 1.04), respectively.[134,139] A summary of the
interactions between raltegravir and etravirine is provided in section 2.1.3.
Raltegravir and Sedatives: The interaction between a single, 2.0 mg dose of midazolam
hydrochloride syrup (2 mg/mL) and raltegravir 400 mg twice daily was evaluated in ten
healthy subjects (7 male, 3 female) who participated in a two-period, open-label, fixed-
sequence dosing study. The GMRs comparing the pharmacokinetic parameters of
midazolam/raltegravir and midazolam alone were 0.92 (90% CI 0.82, 1.03) for the AUC∞
and 1.03 (90% CI 0.87, 1.22) for the Cmax. This result provides additional evidence to
indicate that raltegravir is neither an inducer nor an inhibitor of CYP enzyme activity.[140]
Raltegravir and Antibacterials: The pharmacokinetic interaction between rifampicin 600
mg daily and a single 400 mg dose of raltegravir was evaluated in a two-period, open-label,
fixed-sequence dosing study of ten healthy subjects (7 male, 3 female). Raltegravir exposure
was decreased by 40% when combined with rifampicin, and caution should be used when
these drugs are combined.[141]
Raltegravir and Oral Contraceptives: Combining raltegravir 400 mg twice daily with an
oral contraceptive containing ethinylestradiol and norgestimate does not alter the overall
exposure to the oral contraceptive.[142]
4.2 Elvitegravir
Elvitegravir is currently in phase III clinical trials (figure 1h).
4.2.1 Pharmacology—The molecular weight of elvitegravir is 447.884 g/mol.[143]
Elvitegravir demonstrates potent, selective inhibition of viral DNA integration into host
chromosomal DNA at an adjusted IC50 of 16 nmol/L.[144] Elvitegravir is primarily
metabolized by CYP3A. It undergoes secondary metabolic processing by glucuronidation
through UGT1A1 and UGT1A3. The metabolic activity of UGT1A1 produces the
metabolite M1, while that of UGT1A3 produces the metabolite M4. Both metabolites are
less potent than the parent drug. M1 is 5- to 18-fold less potent and M4 is 10- to 38-fold less
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potent in antiviral activity assays, and both metabolites are not present in plasma in
substantial concentrations. Thus, M1 and M4 do not appear to contribute to the antiviral
activity of elvitegravir.[144]
4.2.2 Pharmacokinetics—Pharmacokinetic data generated in studies with both
treatment-naïve and treatment-experienced populations demonstrated an approximate 20-
fold enhancement in elvitegravir exposure when administered in combination with low-dose
ritonavir. HIV-infected patients taking 800 mg once daily exhibited a mean (CV) AUC24 of
5510 ng • h/mL (54%), Cmax of 940 ng/mL (54%), Cmin of 13.6 (69%) and elimination half-
life of 3.8 hours at steady state. Pharmacokinetic parameters in HIV-infected patients given
elvitegravir 50 mg once daily combined with ritonavir 100 mg included an AUC24 of 8840
ng • h/mL (26%), Cmax of 745 ng/mL (20%), Cmin of 135 ng/mL (37%) and mean
elimination half-life of 8.6 hours.[145] Ritonavir-boosted dosing conditions serve to
enhance the oral bioavailability of elvitegravir while reducing its systemic clearance,
resulting in overall net inhibition of elvitegravir metabolism.
A study in 32 Japanese healthy male subjects determined that the absorption of elvitegravir
is approximately 3-fold higher in the presence of food. Based on this finding, it is
recommended that elvitegravir be taken with food.[146]
4.2.3 Drug-Drug Interactions—Drug-drug interaction studies evaluating the
pharmacokinetics of NRTIs and NNRTIs have been completed. These studies demonstrated
that elvitegravir/ritonavir can be coad-ministered with zidovudine, didanosine, stavudine,
abacavir and tipranavir without the need for dose adjustment. Coad-ministration of
elvitegravir/ritonavir with NNRTIs also does not result in drug-drug interactions. No
additional drug interaction information for elvitegravir is available at this time.
Elvitegravir and Protease Inhibitors: In a study in healthy subjects, coadministration of
elvitegravir with tipranavir/ritonavir was not found to produce any significant change in the
steady-state pharmacokinetics of either drug. Subjects in this crossover study received one
of the following for 14 days: elvitegravir/ritonavir 200 mg/100 mg once daily, tipranavir/
ritonavir 500 mg/200 mg twice daily or elvitegravir 200 mg once daily plus tipranavir/
ritonavir 500 mg/200 mg twice daily. The percent GMRs for the AUCτ, Cmax and Ctrough
during the dosage interval (Cτ) of elvitegravir administered with tipranavir/ritonavir
compared with elvitegravir/ritonavir alone were 92.4 (90% CI 78.7, 108), 106 (90% CI 89.4,
126) and 90.4 (90% CI 69.8, 117), respectively. The GMRs for the AUCτ, Cmax and Cτ of
tipranavir/ritonavir administered with elvitegravir compared with tipranavir/ritonavir alone
were 88.9 (90% CI 80.0, 98.8), 91.6 (90% CI 83.8, 100) and 88.9 (90% CI 77.4, 102),
respectively. No dose adjustment is necessary when coadministering elvitegravir and
tipranavir/ritonavir.[147]
Similarly, a study in 20 healthy subjects showed no significant interaction between
elvitegravir and darunavir/ritonavir. Participants received either elvitegravir/ritonavir 125
mg/100 mg once daily, darunavir/ritonavir 600 mg/100 mg twice daily or elvitegravir 125
mg once daily plus darunavir/ritonavir 600 mg/100 mg twice daily. The GMRs for the
AUCτ, Cmax and Cτ of elvitegravir administered with darunavir/ritonavir compared with
elvitegravir/ritonavir alone were 111 (90% CI 99.1, 122), 113 (90% CI 103, 124) and 118
(90% CI 106, 131), respectively. The GMRs for the AUCτ, Cmax and Cτ of darunavir/
ritonavir administered with elvitegravir compared with darunavir/ritonavir alone were 88.7
(90% CI 82.3, 95.6), 89.4 (90% CI 85.0, 94.1) and 82.8 (90% CI 73.7, 92.9), respectively.
No dose adjustment is necessary when coadministering elvitegravir and darunavir/ritonavir.
[147,148]
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Elvitegravir and Reverse Transcriptase Inhibitors: A study of 31 healthy subjects found
that the mean exposures of a single tablet of didanosine 400 mg were approximately 15%
lower upon coadministration with elvitegravir/ritonavir 200 mg/100 mg. The GMRs for the
didanosine Cmax and AUC administered with elvitegravir/ritonavir compared with
didanosine administered alone were 0.84 (90% CI 0.67, 1.05) and 0.86 (90% CI 0.75, 0.99),
respectively.[144] Similar results were seen with stavudine 40 mg. The GMRs for the
stavudine Cmax and AUC when coadministered with elvitegravir/ritonavir were 0.99 (90%
CI 0.93, 1.06) and 1.07 (90% CI 1.05, 1.08), respectively.[144]
Abacavir undergoes partial hepatic biotransformation via glucuronyltransferase.[149] Since
elvitegravir undergoes secondary metabolism by glucuronyltransferase, the interaction
between elvitegravir/ritonavir 200 mg/100 mg and abacavir was examined in 26 healthy
subjects. All subjects received a single 600 mg dose of abacavir on treatment day 1,
elvitegravir/ritonavir 200 mg/100 mg once daily on treatment days 5–14, and elvitegravir/
ritonavir 200 mg/100 mg plus abacavir 600 mg on treatment day 15. Abacavir
pharmacokinetics were not affected when combined with elvitegravir. The GMRs for the
abacavir Cmax and AUC when administered with elvitegravir/ritonavir were 0.88 (90% CI
0.82, 0.94) and 0.84 (90% CI 0.81, 0.86), respectively.[144] Coadministration with abacavir
had no significant impact on the pharmacokinetic parameters of elvitegravir.
Zidovudine undergoes partial hepatic biotransformation via glucuronyltransferase.[150] The
pharmacokinetic interaction between elvitegravir/ritonavir and zidovudine and its
glucuronide was studied in 28 healthy subjects. Elvitegravir/ritonavir was administered at
200 mg/100 mg once daily and zidovudine at 300 mg twice daily. Pharmacokinetic
parameters were observed with a two-way crossover study design for up to 27 days. Upon
coadministration with elvitegravir/ritonavir, the pharmacokinetic parameters of elvitegravir,
zidovudine and the glucuronide of zidovudine were not altered. The GMRs for the
zidovudine Cmax and AUC were 0.88 (90% CI 0.77, 1.01) and 0.86 (90% CI 0.80, 0.93),
respectively, and the GMRs for the zidovudine glucuronide Cmax and AUC were 1.11 (90%
CI 1.01, 1.21) and 1.05 (90% CI 1.01, 1.08), respectively.[144]
Coadministration of elvitegravir/ritonavir with the fixed-dose combination formula of
emtricitabine/tenofovir disoproxil fumarate did not yield any clinically significant drug-drug
interactions between all compounds in 26 healthy subjects.[151]
An evaluation of the pharmacokinetic interaction between elvitegravir/ritonavir and
lamivudine has not been completed; however, given the lack of a pharmacokinetic
interaction with coadministration of elvitegravir/ritonavir and emtricitabine, a
pharmacokinetic interaction with coadministration of elvitegravir/ritonavir and lamivudine
is unlikely.[151]
No clinically relevant drug-drug interactions between elvitegravir/ritonavir and etravirine
(TMC125) have been found. The results of a study of 34 healthy subjects (17 male, 17
female) demonstrated that coadministration of elvitegravir/ritonavir 150 mg/100 mg once
daily and etravirine (F060) 200 mg twice daily is well tolerated and that no dose adjustment
is required for coadministration of these two drugs. The GMRs for the Cmax, AUC24 and
C24 of elvitegravir (with ritonavir) administered with etravirine compared with elvitegravir
administered alone with ritonavir were 1.07 (90% CI 1.01, 1.13), 1.06 (90% CI 1.0, 1.13)
and 1.06 (90% CI 0.97, 1.16), respectively.[44] The GMRs for etravirine alone were not
reported.
Elvitegravir and Chemokine Receptor Antagonists: A study of the pharmacokinetic
interaction between elvitegravir/ritonavir 150 mg/100 mg twice daily and maraviroc 150 mg
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twice daily in 36 healthy subjects demonstrated no effects on elvitegravir exposure, but
maraviroc exposure increased by 115% (Cmax) and 186% (AUC12). This increased exposure
is within the range of increases observed when maraviroc is administered in combination
with other CYP3A4 inhibitors. Since elvitegravir is metabolized by CYP3A4 and maraviroc
is a CYP3A4 substrate, a reduced dose of maraviroc (150 mg) should be administered when
combined with elvitegravir/ritonavir.[107]
Elvitegravir and Acid-Reducing Agents: The pharmacokinetics of elvitegravir/ritonavir
50 mg/100 mg alone or coadministered with an antacid or omeprazole 40 mg were evaluated
in a study of 12 seronegative subjects. Coad-ministration with the antacid or omeprazole
occurred either simultaneously with elvitegravir/ritonavir or 2 or 4 hours apart from
elvitegravir/ritonavir administration. Coadministration of elvitegravir/ritonavir with the
antacid decreased the Cmax, AUC and Cmin of elvitegravir by 47%, 45% and 41%,
respectively. A 2-hour dose separation between the two drugs decreased elvitegravir
exposure by 10–20%, and a 4-hour dose separation resulted in a < 5% decrease in
comparison with elvitegravir alone. Coadministration of elvitegravir and omeprazole did not
affect the exposures of either drug. Therefore, elvitegravir/ritonavir may be coadministered
with omeprazole but should be separated from an antacid by at least 2 hours.[152]
5. Maturation Inhibitors
5.1 Bevirimat (PA 457)
Bevirimat (PA 457) is the first compound in the novel class of antiretrovirals called
maturation inhibitors, and it is currently in phase II development (figure 1i). Bevirimat
inhibits HIV-1 gag processing, which blocks conversion of p25 to p24, a viral core protein.
This results in defective viral core condensation and noninfectious viral particles. In essence,
this compound is a protease inhibitor, but rather than directly inhibiting the enzyme,
bevirimat attaches to the cleavage site of gag between the capsid protein and SP1. The
capsid protein is a building block for a structure that surrounds and protects the viral RNA,
which is required for maturation into an infectious virion, and SP1 is a transcriptional factor
that HIV uses to activate proviral DNA transcription. Since this cleavage site is highly
conserved, this mechanism may be favourable with respect to the development of resistance.
[153] The IC50 for wild-type HIV-1 is approximately 10 nmol/L (5.8 ng/mL).[153] The
protein binding-adjusted IC90 is estimated to be 2.3 μg/mL.[154]
5.1.1 Pharmacology—The molecular weight of bevirimat is 584.83 g/mol. The protein
binding to human serum albumin is reported to be greater than 99.5%, with no significant
binding to α1-acid glycoprotein (Martin DE, Panacos Pharmaceuticals Inc., personal
communication).
Bevirimat is a substrate of UGTs. The primary pathway of biotransformation is
glucuronidation by UGT1A3.[155] Bevirimat also exhibits weak to moderate inhibition of
the UGTs 1A1, 1A3, 1A4, 1A8, 1A10 and 2B7.[155]
In studies using human liver microsomes, the IC50 values of bevirimat for CYP1A2,
CYP2C19, CYP2D6 and CYP3A4 were >100 μmol/L. The IC50 of CYP2C9 was 10 μmol/
L.[155] In a multiple-dose study in healthy subjects, the GMRs for urinary 6β-
hydroxycortisol/cortisol ratios (a crude measure of CYP3A induction) ranged from 1.02
(90% CI 0.528, 1.96) to 1.36 (90% CI 0.693, 2.67), suggesting no important inductive
effects of bevirimat on CYP3A enzyme activity.[156] Bevirimat does not interact with P-
glycoprotein.[157]
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5.1.2 Pharmacokinetics—In a study in 24 healthy male subjects given single doses of
bevirimat 25 to 250 mg, the tmax was achieved in approximately 2 hours, and the AUC∞ and
Cmax dose-exposure relationships were linear, ranging from approximately 170 to 2000 μg •
h/mL and from 3 to 30 μg/mL, respectively.[154] In a multiple-dose study in 36 healthy
subjects evaluating doses from 25 to 200 mg once daily, an accumulation in bevirimat
exposure was seen between day 1 and day 10. The terminal elimination half-life for all doses
ranged from 56 to 70 hours, and the steady-state oral clearance ranged from 173.9 to 185.2
mL/h.[156] Pharmacokinetic parameters were similar in a multiple-dose study in 32 HIV-
infected patients: the mean (CV) elimination half-life was 62.7 hours (19%) and the mean
oral clearance was 210 mL/h.[158] In phase II studies, doses up to 400 mg are being
investigated.
5.1.3 Drug-Drug Interactions
Bevirimat and Protease Inhibitors: When coadministered with ritonavir, bevirimat
exposure decreases. This is probably due to the UGT-inductive effects of ritonavir.
Beviramat 200 mg once daily was coadministered with ritonavir 100 or 200 mg twice daily.
These combinations were well tolerated. The AUC24 and Cmax of beviramat decreased in a
dose-dependent manner when combined with ritonavir. The GMRs for the AUC24 and Cmax
of beviramat were 0.83 (90% CI 0.75, 0.92) and 0.96 (90% CI 0.87, 1.06), respectively,
when combined with ritonavir 100 mg twice daily. When combined with ritonavir 200 mg
twice daily, the GMRs for the AUC24 and Cmax of beviramat were 0.69 (90% CI 0.62, 0.77)
and 0.83 (90% CI 0.75, 0.92), respectively. No notable changes were seen in ritonavir
exposures.[159] The clinical significance of these changes in exposure are being further
evaluated.
In a study of 48 healthy subjects, the combination of bevirimat and atazanavir was well
tolerated, with no increase in bilirubin levels and no pharmacokinetic interactions being
observed. Bevirimat 200 mg once daily was combined with atazanavir 400 mg once daily.
Compared with the exposure of either drug alone, the GMRs for the AUC24 and Cmax were
0.92 (90% CI 0.81, 1.09) and 0.96 (90% CI 0.85,1.09), respectively, for bevirimat and 0.94
(90% CI 0.78, 1.13) and 0.94 (90% CI 0.82, 1.07), respectively, for atazanavir.[160]
Therefore, no dose adjustment should be necessary when combining bevirimat and
atazanavir.
6. Conclusions
Potent new antiretroviral drugs in existing and novel classes offer treatment-experienced
HIV-infected patients the chance of durable, long-term suppression of HIV replication.
However, the increase in antiretroviral drug options also increases the complexity of using
novel combinations of these agents together. Most new agents have significant drug-drug
interaction challenges, and the clinical significance of these interactions cannot always be
determined in well controlled studies that take place in healthy subjects. A thorough
knowledge of how these drugs are metabolized and eliminated from the body will assist in
predicting and managing important and potentially detrimental drug-drug interactions.
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Chemical structures of (a) darunavir, (b) etravirine, (c) rilpivirine, (d) maraviroc, (e)
vicriviroc, (f) INCB 9471 (g) raltegravir, (h) elvitegravir and (i) bevirimat.
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Table III
Interactions of new/investigational antiretrovirals (ARVs) with other ARVs: second-generation non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and CCR5 antagonists
Drug class Target drug Second-generation NNRTI CCR5 antagonist
etravirine maraviroc
PI Darunavir, RTV boosted ↔, no dose adjustment needed ↔, no dose adjustment needed
NNRTI Etravirine ↔, no dose adjustment needed
CCR5 antagonist Maraviroc ↓, adjust dose
Integrase inhibitor Raltegravir ↓, no dose adjustment needed
Elvitegravir, RTV boosted ↔, no dose adjustment needed ↔, no dose adjustment needed
PI = protease inhibitor; RTV = ritonavir; ↑ indicates an increase in the concentration of the target drug; ↓ indicates a decrease in the concentration
of the target drug; ↔ indicates no change in the concentration of the target drug.
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